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A B S T R A C T
Background
Faecal incontinence (FI) and constipation are both socially-embarrassing and physically-disabling conditions that impair quality of
life. For both, surgery may be required in a minority of people when more conservative measures fail. However, the invasiveness and
irreversible nature of direct surgery on bowel and sphinctermuscles, poor long-term outcomes andwell-established compIications makes
such procedures unappealing for these benign conditions. A less-invasive surgical option to treat faecal incontinence and constipation
is direct, low-voltage stimulation of the sacral nerve roots, termed sacral nerve stimulation (SNS). SNS has become the first line surgical
treatment for FI in people failing conservative therapies. Its value in the treatment of constipation is less clear.
Objectives
To assess the effects of sacral nerve stimulation using implanted electrodes for the treatment of faecal incontinence and constipation in
adults.
Search methods
We searched theCochrane Incontinence Group Specialised Register, which contains trials identified from the Cochrane Central Register
of Controlled Trials (CENTRAL), MEDLINE, MEDLINE In-Process, ClinicalTrials.gov, the World Health Organization (WHO)
ICTRP and handsearched journals and conference proceedings (searched 5 February 2015), EMBASE (1 January 1947 to 2015 Week
5), and the reference lists of retrieved relevant articles.
Selection criteria
All randomised or quasi-randomised trials assessing the effects of SNS for faecal incontinence or constipation in adults.
Data collection and analysis
Two review authors independently screened the search results, assessed the methodological quality of the included trials, and undertook
data extraction.
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Main results
Six crossover trials and two parallel group trials were included.
Six trials assessed the effects of SNS for FI. In the parallel group trial conducted by Tjandra, 53 participants with severe FI in the SNS
group experienced fewer episodes of faecal incontinence compared to the control group who received optimal medical therapy (mean
difference (MD) −5.20, 95% confidence interval (CI) −9.15 to −1.25 at 3 months; MD −6.30, 95% CI −10.34 to −2.26 at 12
months). Adverse events were reported in a proportion of participants: pain at implant site (6%), seroma (2%) and excessive tingling
in the vaginal region (9%).
In the parallel group trial carried out by Thin, 15 participants with FI in the SNS group experienced fewer episodes of FI compared
with the percutaneous tibial nerve stimulation (PTNS) group (MD −3.00, 95% CI −6.61 to 0.61 at 3 months; MD −3.20, 95% CI
−7.14 to 0.74 at 12 months). Adverse events were reported in three participants: mild ipsilateral leg pain during temporary testing (n
= 1); and stimulator-site pain following insertion of neurostimulator (n = 2).
In the crossover trial by Leroi 7 of 34 recruited participants were excluded from the crossover due mainly to complications or immediate
device failure. Twenty-four of the remaining 27 participants while still blinded chose the period of stimulation they had preferred.
Outcomes were reported separately for 19 participants who preferred the ’on’ and five who preferred the ’off ’ period. For the group of
19, the median (range) episodes of faecal incontinence per week fell from 1.7 (0 to 9) during the ’off ’ period to 0.7 (0 to 5) during the
’on’ period; for the group of five, however, the median (range) rose from 1.7 (0 to 11) during the ’off ’ period compared with 3.7 (0 to
11) during the ’on’ period. Four of 27 participants experienced an adverse event resulting in removal of the stimulator.
In the crossover trial by Sørensen and colleagues, participants did not experience any FI episodes in either the one-week ‘on’ or ‘off ’
periods.
In the crossover trial by Vaizey, participants reported an average of six, and one, episodes of faecal incontinence per week during the
’off ’ and ’on’ periods respectively in two participants with FI. Neither study reported adverse events.
In the crossover trial by Kahlke, 14 participants with FI experienced significantly lower episodes of FI per week during the stimulator
’on’ (1 (SD, 1.7)) compared with the ’off ’ period (8.4 (SD, 8.7)). Adverse events reported include: haematoma formation (n = 3);
misplacement of tined lead (1); and pain at stimulator site (n = 1).
Two trials assessed SNS for constipation. In the Kenefick trial, the two participants experienced an average of two bowel movements
per week during the ’off ’ crossover period, compared with five during the ’on’ period. Abdominal pain and bloating occurred 79%
of the time during the ’off ’ period compared with 33% during the ’on’ period. No adverse events occurred. In contrast, in the trial
by Dinning with 59 participants, SNS did not improve frequency of bowel movements and 73 adverse events were reported, which
included pain at site of the implanted pulse generator (32), wound infection (12), and urological (17) events.
Authors’ conclusions
The limited evidence from the included trials suggests that SNS can improve continence in a proportion of patients with faecal
incontinence. However, SNS did not improve symptoms in patients with constipation. In addition, adverse events occurred in some
patients where these were reported. Rigorous high quality randomised trials are needed to allow the effects of SNS for these conditions
to be assessed with more certainty.
P L A I N L A N G U A G E S U M M A R Y
Sacral nerve stimulation for treating faecal incontinence and constipation in adults
Importance of the review/Background:Faecal incontinence occurs when a person passes stools without the usual control. Constipation
is harder to define but generally describes a situation in which a person feels that their bowel opening is unsatisfactory (usually a
combination of difficulty or infrequency of passing stools). Both conditions can severely affect people’s quality of life. There are many
non-surgical treatments for both conditions but occasionally surgery is required when other options fail. Sacral nerve stimulation (SNS)
is a relatively new treatment for these conditions. It involves implanting a battery-powered stimulator unit in the buttock. This is
connected to electrodes which rest on the nerves in the lower spine. The stimulator then continuously sends impulses to the nerves and
muscles that control the bowel and anus. Initially, a temporary electrode lead is connected to a portable battery unit outside the body.
If symptoms are improved enough, this is replaced by the implanted battery.
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Main findings: This review evaluated the published evidence for the use of SNS for patients with faecal incontinence or constipation
from six trials of SNS for faecal incontinence (219 participants) and two trials of SNS for constipation (61 participants). Two of the
faecal incontinence trials had a ’parallel group design’, which means that one group of participants received SNS and the other control
group did not receive SNS throughout the trial. The remaining six trials had a ’crossover design’, in which the participants experienced
equal periods with stimulation ’off ’ then ’on’, or vice versa. The level of stimulation was such that participants could not tell whether
the system was ’on’ or ’off ’.
SNS for faecal incontinence: In the two ’parallel group’ trials, 53 and 15 participants with faecal incontinence who were in the SNS
group experienced fewer episodes of faecal incontinence compared to the control group at 3 and 12 months. In the first crossover trial,
24 participants who completed the trial chose the period of stimulation they had preferred while still unaware whether this was ’on’
or ’off ’. Nineteen participants who preferred the ’on’ period experienced 59% fewer episodes of FI per week during the ’on’ period,
and 5 participants who preferred the ’off ’ period experienced 118% more episodes of FI per week. In the second crossover trial, the
participants did not experience episodes of FI during either the ’on’ or the ’off ’ periods. In the third trial, participants experienced
83% fewer episodes of faecal incontinence during the ’on’ compared with the ’off ’ period. In the fourth crossover trial participants
experienced 88% fewer episodes of faecal incontinence during the ’on’ period compared with the ’off ’ period.
SNS for faecal incontinence-adverse effects: Not all trials reported adverse effects after SNS. The two ’parallel group’ trials reported
only minor complications, in 10% of SNS participants in the first study, and in 3 participants in the second study. In the first crossover
study 7 out of 34 participants were excluded from crossover due mainly to complications. Four out of 27 participants with an implanted
system in this study experienced a problem that led to the device being removed. The participants in the fourth crossover trial experienced
some complications with the SNS implanted electrode such as pain (one person), misplacement of the tined lead (one person) and
haematoma (swelling containing blood) (three people).
SNS for constipation: In one trial assessing SNS for constipation, two participants reported an increase of 150% in the frequency of
passing stools per week, and time with abdominal pain and swelling went down from 79% during the ’off ’ period to 33% during the
’on’ period. However, in the much larger second trial assessing SNS for constipation, in 59 participants SNS did not improve frequency
of bowel movements.
Limitations of the review: The limited evidence suggests that SNS can improve continence in some people with faecal incontinence.
SNS did not improve symptoms in patients with constipation. Larger, good-quality trials are needed to provide more reliable evidence
on the effectiveness of SNS for these two conditions.
B A C K G R O U N D
Description of the condition
The act of defaecation is dependent on the co-ordinated functions
of the colon, rectum and anus. Considering the complexity of
neuromuscular (sensory and motor) functions required to achieve
planned, conscious, and effective defaecation (Scott 2011), it is
no surprise that disturbances to perceived ‘normal’ function occur
commonly at all stages of life. Clinically, such problems principally
encompass presentations with faecal incontinence or constipation.
Although usually described separately (as in this review), it should
be noted that considerable overlap between these symptoms occurs
at all ages of presentation (Burgell 2012; Rao 2004a).
Faecal incontinence
Faecal incontinence (FI) is a socially-embarrassing and physically-
disabling condition. It may be defined as the uncontrolled loss
of faeces (liquid or solid) from the bowel. It may occur passively
(without the person affected being aware of passing faeces); or be
preceded by urgency (a sense of an urgent need to defaecate); or
both, commonly termed ’mixed faecal incontinence’. A further
term-‘post-defaecatory seepage or leakage’-is also sometimes used
to denote passive loss of small amounts of faeces retained after
incomplete evacuation (Rao 2004b).
Faecal incontinence is a common problem, although the true
prevalence is hard to determine due to under-reporting (Johanson
1996; NICE 2007). US population surveys suggest the prevalence
of FI ranges anywhere from 2% to 17% affecting both men and
women (Nelson 2004; Peery 2012; Whitehead 2009). In the UK,
it is estimated that up to 10% of adults experience involuntary
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loss of solid or liquid stool causing physical, psychological and
social disability; 0.5% to 1% of adults experience regular faecal
incontinence that severely affects their quality of life (NICE 2007;
Norton 2007). Although awareness of the health burden from fae-
cal incontinence has increased in recent years, it still largely re-
mains a taboo problem (Johanson 1996). Considering the higher
prevalence with advancing age (Brown 2010), FI may be an even
greater problem in the future. The prevalence of FI approaches
50% in nursing homes (Nelson 1998).
Faecal incontinence may result from:
• damage to the anal sphincter mechanism (either from direct
trauma or damage to its nerve supply);
• age-related degeneration of the sphincter;
• spinal injury;
• other neurological causes; or
• non-sphincter causes (e.g. diarrhoea, dementia) (Lunniss
2004).
The well-documented association between FI and birth injuries
has led to the belief that pudendal nerve injury or direct damage
to the anal sphincter complex is themain pathophysiology (Sultan
1993; Sultan1997a; Sultan1997b). In truth,most FI is caused by a
complex interplay of pathophysiological factors including aberrant
anorectal sensation and colorectal motility, as well as structural
changes or damage to the pelvic floor and sphincter complex.
Indeed, women who sustain obstetric trauma often do not present
with symptoms of FI until up to 30 years postpartum (Lunniss
2004; Rao 2004a).
With such aetiological and pathophysiological heterogeneity, FI
remains a challenging condition to directly address by any single
treatment. Conservative measures include:
• dietary modification;
• bowel retraining;
• anti-diarrhoeal medication (Ehrenpreis 2007; Omar 2013);
• biofeedback (Enck 2009; Norton 2003; Norton 2004); and
• supportive devices such as absorbent padding or plugs.
However, such measures have, at best, a lasting success in only ap-
proximately 50% of patients (Otto 2010); thus surgical treatment
is often considered. The latter may include:
• bulking agents (Graf 2011);
• direct anal sphincter repair (Malouf 2000);
• artificial bowel sphincter (Altomare 2004); and
• dynamic graciloplasty (Baeten 1991).
All of these operations have well-established complications and
high long-term failure rates (Altomare 2004;Malouf 2000).While
several newer treatments, such as autologous muscle cell therapy,
magnetic sphincter augmentation and sphincter bulking agents,
are at an early clinical evaluation stage (Carr 2013; Lehur 2010;
Ratto 2011), many patients may still resort to a stoma (usually
colostomy) for significant intractable symptoms.
Constipation
Constipation is common in adults and children and up to 20% of
the population report this symptomdepending on definitions used
(2% to 28% adults; 0.7% to 30% children) (Sonnenberg 1989;
Stewart 1999; van den Berg 2006), with a higher prevalence in
women (McCrea 2009; Mugie 2011; Sonnenberg 1989), and the
elderly (Gallegos-Orozco 2012; Norton 2006). Chronic constipa-
tion (CC), usually defined as more than six months of symptoms,
is less common (Probert 1995), but results in half amillionUKGP
consultations per annum. A proportion of the population suffer
symptoms which are both chronic and more disabling (probably
about 1% to 2% of the population) (Cook 2009). Such patients,
who are most often female (Knowles 2003), are usually referred to
secondary care with many progressing to tertiary specialist inves-
tigation. Patient dissatisfaction is high in this group: nearly 80%
feel that laxative therapy is unsatisfactory (Wald 2008), and the
effect of symptoms onmeasured QOL is significant (Irvine 2002).
Chronic constipation consumes significant healthcare resources:
in the US in 2012, a primary complaint of constipation was re-
sponsible for 3.2 million physician visits (Peery 2012), resulting
in (direct and indirect) costs of $1.7 billion. In the UK, it is esti-
mated that 10% of district nursing time is spent on constipation
(Poulton 1999), and the annual spend on laxatives exceeds £80
million, with £17.4 million prescribed in 2012 (HSCIC 2013).
Management of chronic constipation is a major problem due to
its high prevalence and lack of widespread specialist expertise. In
general, a step-wise approach is undertaken, with first-line conser-
vative treatment such as lifestyle advice and laxatives (NHS 2012),
followed by nurse-led bowel retraining programs, often includ-
ing focused biofeedback (Woodward 2014), and psychosocial sup-
port. Although these treatments may improve symptoms in more
than half of patients, they are very poorly standardised and are
not universally successful. While some hope has been offered by a
range of new prokinetic and pro-secretory drugs (Camilleri 2008;
Johanson 2008), patients with intractable symptoms and impaired
QOL may be offered a range of costly, irreversible surgical in-
terventions with unpredictable results (Knowles 1999; Knowles
2009), sometimes resulting in major adverse events or a perma-
nent stoma.
Description of the intervention
Neuromodulation is one of the fastest growing areas of medicine
and may be defined as a technology that impacts upon neural in-
terfaces to produce benefit. The concept of electrical stimulation
of the pelvic floormay be traced back to the early 19th century with
several methods of direct neuromuscular stimulation developed
subsequently (Hopkinson 1966). In the last 20 years, a group of
treatments have been developed that employ chronic, low-voltage
electrical stimulation to recruit residual function of pelvic organs
by direct or indirect stimulation of the sacral spinal nerves (Matzel
1995; Matzel 1990). Such developments, which in general have
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evolved from the urology field (Brindley 1974; Tanagho 1989),
have the potential to bridge the gap between conservative treat-
ments and potentially hazardous direct surgery to the bowel or
anal sphincter. An attraction of these treatments is that, unlike
direct surgery to the sphincter or colon, they have the potential
to modify all aspects of the co-ordinated neuromuscular functions
required for defaecation (Carrington 2011), and on this basis may
benefit both FI and chronic constipation. Further, neuromodula-
tion has the intrinsic qualities of dose variation and reversibility
which are rarely possible with other surgical therapies. The most
established of these treatments is Sacral Nerve Stimulation (SNS).
SNS involves direct, chronic, low-voltage electrical stimulation of
the sacral nerve roots by the siting of an electrode via a sacral fora-
men (S3 is the optimal site for most patients). Whilst there has
been an evolution of systems over time (MacDonagh 1990;Matzel
1990), in its most common current form SNS utilises a percuta-
neously-sited, commercially-manufactured quadripolar electrode
lead system connected to an implanted pulse generator (Inter-
Stim® Therapy, Medtronic, Inc., Minneapolis, US) buried in the
subcutaneous fat of the buttock. The Medtronic system also al-
lows for a temporary percutaneous nerve evaluation (PNE) phase
which allows the patient to trial the impact of sacral nerve stimu-
lation on their lifestyle and test the feasibility of success before the
more expensive permanent stimulator is implanted.
SNS techniques are well described in the literature, with agree-
ment that this can be carried out effectively and safely under both
general anaesthetic, and local anaesthetic with or without sedation
(Mitchell 2011); with minimal reported morbidity (overall com-
plications rates of 5% to 26% (Tjandra 2004)); and no reported
mortality (Wong 2011).
How the intervention might work
Understanding of the mechanism of action of SNS is universally
acknowledged to be an important knowledge gap limiting poten-
tial for patient selection, technology and procedural optimisation
that could focus therapy, improve outcomes and reduce healthcare
costs (Carrington 2014). Traditional understanding of the patho-
physiology and surgicalmanagement of FI held that sphincter ‘bar-
rier’ had primacy. It is now clear that whilst sphincter disruption
(resulting from, for example, obstetric injuries) is still relevant to
the development of FI, it is only one factor in complex defaecatory
dysfunction that involves alteration in unconscious anorectal and
pelvic reflexes and conscious modulation by the central nervous
system.
The importance of sensory dysfunction on both urinary and bowel
control is being increasingly appreciated and there is strong evolv-
ing evidence (in man (Knowles 2012); and experimental animals
(Evers 2014; Griffin 2011)) that the mechanism of action of SNS
results primarily from modulation of afferent nerve activity rather
than motor effects on the anal sphincter itself (Carrington 2014;
Duelund-Jakobsen 2013; Patton 2013). The effects of SNS on
colonic motor activity have also been studied. Data suggest that
SNS, but not sham stimulation, increased the frequency of retro-
grade propagated sequences throughout the colon in participants
with FI (Patton 2013) i.e. effects anticipated to delay colonic tran-
sit. In contrast SNS also increased colonic propagating sequences
in participants with slow-transit constipation (Dinning 2012).
This disparity of effect may reflect baseline differences of colonic
motor activity, however further study is required to explain these
seemingly counter-intuitive findings.
Why it is important to do this review
SNS is now considered the first-line surgical intervention for peo-
ple with FI for whom conservative treatments have failed (NICE
2007). Over 100 published case series (of over 2000 participants),
including some quite large prospective studies (Melenhorst 2007;
Wexner 2010), attest to the general success of this approach,
and SNS has regulatory approval in most major health systems
(NHS 2013; NICE 2007). Recent systematic review data show
favourable mid- and long-term positive outcomes for SNS of ap-
proximately 80% based on a greater than 50% reduction in FI
episodes, although this figure is reduced to approximately 60%
when results are reanalysed using all available participants who
start therapy as the denominator (comparable with intention-to-
treat principles) (Thin 2013).
In comparison with FI, the role of SNS in treating chronic consti-
pation is less well established. However, it carries the same attrac-
tions: namely the avoidance of potentially hazardous direct surgery
to the colon or pelvic floor. Unfortunately, favourable results of
a European experience of SNS on 62 participants (63% success-
ful) with chronic constipation, (of mixed or specific pathophysiol-
ogy (Kamm 2010 and Knowles 2012 respectively)) have not been
replicated by others (Holzer 2008; Maeda 2010; Vitton 2009).
On this basis SNS has not yet, in general, been commissioned as
a treatment for constipation in most health systems.
Despite the implicit advantages and reported success of SNS over
the last 20 years (especially for FI), one major drawback remains:
the initial costs of SNS are still considerable both in terms of direct
equipment cost and indirect hospital admission costs (Dudding
2008). On this basis, health practitioners need to be reassured of
the efficacy of SNS therapy. This systematic review updates the
available evidence from randomised controlled trials.
O B J E C T I V E S
To assess the effects of sacral nerve stimulation using implanted
electrodes for the treatment of faecal incontinence and constipa-
tion in adults.
The following comparisons were made:
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1. Sacral nerve stimulation (implanted) versus control or sham
stimulation
2. Sacral nerve stimulation (implanted) versus another active
treatment
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised, quasi-randomised and crossover trials.
Crossover trials have been identified with the suffix ’#’.
Types of participants
Adults with faecal incontinence or constipation, including func-
tional, structural and neurological causes.
Types of interventions
One arm of the trial had to use a surgically implanted device to
provide sacral nerve stimulation.
Comparators considered included:
1. mock, sham or placebo treatment; and
2. any alternative active intervention considered appropriate
by the trialists, such as dynamic graciloplasty, artificial bowel
sphincter implants, stoma formation, absorbent pads, anal plugs,
and physical or behavioural therapies.
Trials in which both arms used active implanted sacral nerve stim-
ulation were not included in this review. Newer treatment modali-
ties including magnetic and transcutaneous stimulation were con-
sidered.
Types of outcome measures
Primary outcomes
Faecal incontinence
The primary outcomes were: (a) cure or improvement of incon-
tinence; and (b) quality of life. Outcomes were considered in the
following categories:
(1) Faecal incontinence (number cured or improved, episodes of
faecal incontinence, urgency, ability to defer defaecation, use of
pads, use of anal plugs, incontinence score, and need for further
treatment such as medication or surgery).
(2) Quality of life (generic and condition-specific).
Constipation
The primary outcomes were: (a) cure or improvement of consti-
pation; and (b) quality of life. Outcomes were considered in the
following categories:
(1) Constipation (number cured or improved, frequency of bowel
movements, abdominal pain/bloating, constipation score, and
need for further treatment such as medication or surgery).
(2) Quality of life (generic and condition-specific).
Secondary outcomes
Faecal incontinence
Outcomes were considered in the following categories:
(1) Surrogatemeasures, such as anorectal manometry (resting pres-
sure, maximum squeeze pressure, rectal sensory threshold to bal-
loon distention, sensation of urgency to balloon distention, and
maximum tolerated rectal volume to balloon distention).
(2) Adverse effects (infection or pain or both at the implantation
site; displacement of the electrodes; technical failure requiring re-
moval or change in urinary function, or both).
(3) Health economics (costs, resource implications and cost-effec-
tiveness or cost utility evaluation).
(4) Other outcomes (other outcome measures quoted by trial au-
thors and judged to be important by the authors of this review).
Constipation
Outcomes were considered in the following categories:
(1) Surrogatemeasures, such as anorectal manometry (resting pres-
sure, maximum squeeze pressure, rectal sensory threshold to bal-
loon distention, sensation of urgency to balloon distention, and
maximum tolerated rectal volume to balloon distention).
(2) Adverse effects (infection or pain or both at the implantation
site; displacement of the electrodes; technical failure requiring re-
moval or change in urinary function, or both).
(3) Health economics (costs, resource implications, and cost-ef-
fectiveness or cost utility evaluation).
(4) Other outcomes (other outcome measures quoted by trial au-
thors and judged to be important by the authors of this review).
Search methods for identification of studies
We did not impose any language or other limitations on the
searches described below.
Electronic searches
This review drew on the search strategy developed for the Incon-
tinence Group as a whole. Relevant trials were identified from
the Cochrane Incontinence Group Specialised Trials Register. The
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methods used to derive this, including the search strategy, are de-
scribed under the Group’s module in the Cochrane Library. The
register contains trials identified from the Cochrane Central Reg-
ister of Controlled Trials (CENTRAL), MEDLINE, MEDLINE
In-Process, ClinicalTrials.gov, WHO ICTRP and hand searching
of journals and conference proceedings.
The Incontinence Group Specialised Register was searched using
the Group’s own keyword system; the search terms used are given
in Appendix 1.
Date of the most recent search of the register for this review: 5
February 2015.
The majority of the trials in the Incontinence Group’s Specialised
Register are also contained in CENTRAL.
Also Embase (1 January 1947 to 2015 Week 5) was searched on
5 February 2015 using the search strategy given in Appendix 2.
Only the years 2010 to 2015 (inclusive) were searched as these
years were not covered by theCochraneCollaboration’s centralised
search of Embase for CENTRAL at this time.
Searching other resources
All reference lists of identified trials were searched.
Data collection and analysis
Analyses of crossover trials were based on data available from in-
cluded relevant trials. Meta-analysis could not be performed be-
cause of variation in reported outcomes.
Selection of studies
Two review authors (AA, MAT) independently evaluated reports
of all potentially eligible studies for inclusion. Any disagreements
were resolved by discussion or arbitration by the review group at
consensus meetings.
Data extraction and management
Two review authors (AA, MAT) independently undertook data
extraction for the five new trials that were added (Dinning 2015#;
Kahlke 2015#; Sørensen 2010#; Thin 2015; Tjandra 2008); and
checked and updated the information from the previously in-
cluded trials, in particular ’Risk of bias’ assessment. We planned to
seek clarification from the trialists where data were collected but
not reported, or reported in a form unsuitable for the review. In-
cluded data were processed as described in theCochrane Handbook
for Systematic Reviews of Interventions (http://www.cochrane.org/
resources/handbook/hbook.htm) (Higgins 2011). Any disagree-
ments were resolved by discussion or arbitration by the review au-
thors. Data from crossover were entered into Other Data Tables.
Assessment of risk of bias in included studies
Two review authors (AA, MAT) independently assessed the
methodological quality of all the included trials using the
Cochrane Incontinence Group’s assessment criteria. Studies were
not excluded from the review on the basis of methodological qual-
ity. Any disagreements were resolved by discussion or arbitration
by all the review authors.
Measures of treatment effect
We planned to combine data, if this was considered appropriate,
by applying fixed-effect methods, with relative risk used for di-
chotomous outcomes and weighted mean difference used for con-
tinuous outcomes.
Dealing with missing data
We sought clarification on missing data from the trialists and,
when available, they were included in the final abstraction and
analysis.
Assessment of heterogeneity
If visual inspection or the Chi² test had suggested heterogeneity at
the 10% level thenwe planned to explore the reasons for this. If the
level of heterogeneity was serious enough to affect the validity of
the results then applying a random-effects method would be con-
sidered. Alternatively, if it was considered inappropriate to com-
bine data from the included trials we planned instead to present
a narrative synthesis of the results of the primary studies. In the
event it was not possible to find any data suitable for meta-analy-
ses, and all the data are presented in ’Other Data’ tables.
Assessment of reporting biases
All included trials were formally assessed for methodological qual-
ity, including for selective reporting using appropriate tools in
Cochrane’s Review Manager (RevMan) software. The method-
ological quality of included trials are reported in ’Risk of bias’ fig-
ure and summary.
Data synthesis
We planned to combine data by applying fixed-effect methods
when appropriate.
Subgroup analysis and investigation of heterogeneity
If the evidence had allowed, we planned to undertake sub-group
analysis on the following categories of participants:
(1) participants with faecal urgency;
(2) participants with structural defects of the anal sphincter;
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(3) participants with partial spinal cord injury; and
(4) participants with central neurological disease.
Sensitivity analysis
Weplanned to use sensitivity analysis to test the effects of included
studies of poor methodological quality, if appropriate.
R E S U L T S
Description of studies
Please see ’Characteristics of included studies’ and ’Characteristics
of excluded studies’ tables for further details.
Results of the search
A total of 197 records, identified by the literature search, were
screened and 16 full-text articles of potentially eligible studies were
obtained. There were 10 reports of 8 included studies and 3 re-
ports of 3 excluded studies. Additionally there were three reports
of three ongoing studies, details of which can be found in the
Characteristics of ongoing studies table. Figure 1 illustrates the
process of the literature search and selection of studies for the up-
date of this review.
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Figure 1. PRISMA flow diagram
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Included studies
Eight potentially relevant trials identified by the search strategy
were included (Dinning 2015#; Kahlke 2015#; Kenefick 2002#;
Leroi 2005#; Sørensen 2010#; Thin 2015; Tjandra 2008; Vaizey
2000#).
Six trials assessed the effects of sacral nerve stimulation (SNS) for
faecal incontinence (Kahlke 2015#; Leroi 2005#; Sørensen 2010#;
Thin 2015; Tjandra 2008; Vaizey 2000#).
Two trials assessed the effects of SNS for constipation (Dinning
2015#; Kenefick 2002#).
Design
Six trials had a crossover design (Dinning 2015#; Kahlke 2015#;
Kenefick 2002#; Leroi 2005#; Sørensen 2010#; Vaizey 2000#),
while two had a parallel-group design (Thin 2015; Tjandra 2008).
In the study carried out byThin 2015 patients were allocated to re-
ceive either SNS or percutaneous tibial nerve stimulation (PTNS).
In the SNS group participants underwent a trial with temporary
SNS for two weeks; those who exhibited a good response (at least
50% reduction in FI) had permanent SNS implantation. In the
trial conducted by Tjandra 2008 all participants attended mul-
tidisciplinary pelvic floor clinic and were randomised to sacral
nerve stimulation (SNS group) or optimal medical therapy (con-
trol group). In the SNS group all participants were tested for a
minimum of seven days and participants who exhibited a good
response underwent permanent implantation with a quadripolar
electrode for the 12 months of follow up. The electrode combi-
nation with best perception of muscle contraction of perineum
and anal sphincter with least voltage was selected for permanent
stimulation.
Moreover, in the trials conducted by Kenefick 2002# and Vaizey
2000#, participants underwent two two-week intervals with sub-
sensory stimulation either ’on’ or ’off ’. There was no interval be-
tween the treatment periods.
Similarly, in the trial conducted by Sørensen 2010#, participants
underwent two one-week intervals with stimulation either ‘on’ or
‘off ’. There was no interval between the treatment periods.
In the trial carried out by Dinning 2015#, participants underwent
three weeks of temporary peripheral nerve stimulation, then all
patients underwent permanent SNS electrode implantation. Par-
ticipants were then randomised to receive subsensory stimulation
or sham for three weeks; and after a two-week washout period
the group that received sham stimulation now received subsensory
stimulation for three weeks and vice versa. Then, following a fur-
ther two-week washout period, participants were re-randomised
to receive either sham or suprasensory stimulation for three weeks.
Participants then underwent a further two-week washout period,
after which participants who received sham stimulation now un-
derwent suprasensory stimulation for three weeks and vice versa.
In the trial conducted by Kahlke 2015#, after permanent implan-
tation 31 patients had a minimum of 3 months with the stimula-
tor turned on. Then participants were invited to take part in the
crossover study. Sixteen participants were enrolled, who were sub-
sequently randomised in a crossover design to ’on’ or ’off ’ stimu-
lation, each period lasting three weeks. At the end of each three-
week period the stimulator was programmed to the opposite mode
(’off ’ or ’on’). While still blinded at the end of the crossover pe-
riod participants selected the period of stimulation they had pre-
ferred (’off ’ or ’on’). The mode of stimulation corresponding to
the preferred period (’off ’ or ’on’) was continued for a further three
months.
In the trial conducted by Leroi 2005#, after definitive ’permanent’
implantation each participants had a one- to three-month phase
when the stimulator was turned ’on’ (postimplantation period),
to optimise the effectiveness of stimulation by determining the
most effective parameters of stimulation (choice of stimulation
electrodes and intensity of stimulation). At the end of the postim-
plantation period, participants were randomised in a crossover de-
sign to ’on’ or ’off ’ stimulation for a two-month period. At the
end of the first month, the neurostimulator was programmed to
the opposite mode (’off ’ or ’on’), and monitoring continued for a
second month. There was no interval between the two treatment
periods. At the end of the crossover period, while still blinded, the
participants chose the period of stimulation (’on’ or ’off ’) they had
preferred. The mode of stimulation corresponding to the selected
period (’on’ or ’off ’) was then continued for a three-month follow-
up period. If the participant could not choose between one of the
two periods, the stimulator was turned ’on’.
Sample sizes
In total the trials enrolled 280 people, of whom 177 received a
definitive implant. The trials included:
Faecal incontinence:
• Vaizey 2000# included two participants;
• Kahlke 2015# enrolled 16 participants, all received a
permanent SNS implant;
• Leroi 2005# enrolled 34 participants, of whom 27 went on
to receive a permanent implant;
• Sørensen 2010# enrolled 7 participants;
• Thin 2015 enrolled 40 participants, of whom 16 received a
permanent SNS implant;
• Tjandra 2008 enrolled 120 participants, of whom 53
received a permanent implant.
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Constipation
• Dinning 2015# enrolled 59 participants of whom 55 had
permanent implant; and
• Kenefick 2002# included two participants;
Setting
Two trials were carried out in the same hospital centre (St. Mark’s
Hospital, Harrow); neither reported the time period during which
the trial was undertaken (Kenefick 2002#; Vaizey 2000#). The
third trial was carried out in a single centre located in Germany
(Kahlke 2015#). The fourth trial was a multicentre trial (number
of centres not stated), set in France, which took place during the
period February 2000 to February 2003 (Leroi 2005#). The fifth
trial was a single-centre trial set in Denmark (Sørensen 2010#).
The sixth trial was a two-centre trial set in two London hospitals
(Royal LondonHospital andUniversity College LondonHospital,
UK) (Thin 2015). The seventh trial was a single-centre trial set in
Australia (Tjandra 2008). The eighth trial was a two-centre trial
conducted in Australia (Dinning 2015#).
Participants
Of 280 participants enrolled, 246 (87.9%) were women.
Compliance and treatment received
In the trial carried out by Thin and colleagues, 8 of the 23 par-
ticipants in the SNS group did not receive permanent implanta-
tion (Thin 2015). The reasons cited include: intercurrent illness
requiring urgent medical management (n = 1); symptoms resolved
(n = 1); declined further participation (n = 2); failed temporary
SNS (n = 3); withdrawn from treatment for urgent investigation
of a new pararectal cyst (n = 1). In the trial conducted by Tjandra
and colleagues 7 of the 60 participants in the SNS arm did not re-
ceive permanent implantation (Tjandra 2008). The reasons were:
cannulation of foramen with electrode was not achieved due to
previous back surgery, which required bone graft from the sacral
area (n = 1); insufficient therapeutic response with peripheral nerve
evaluation (n = 5); and concern participants might require mag-
netic resonance imaging of brain post excision of meningioma (n
= 1).
In the trial carried out by Kahlke 2015#, out of the 16 partic-
ipants enrolled, 2 discontinued; the reasons were (i) participant
turned stimulator ’on’ with handheld device because she had be-
come completely incontinent (n = 1); (ii) participant fell on lower
back leading to breakage of permanent lead (n = 1).
In the trial conducted by Leroi 2005# 10 of 34 participants pre-
maturely discontinued the trial. The reasons for discontinuation
were: device-related adverse events (n = 4); protocol violation (n =
3); insufficient therapeutic response (n = 1); no return to follow-
up (n = 1); and adverse event (stroke) not related to SNS (n = 1).
In the trial conducted by Dinning 2015# four participants did not
receive permanent SNS implant due to depression (n = 1); too far
to travel (n = 2); and could not commit (n = 1). Of those who
received permanent implant 2 participants discontinued the study
due to pregnancy (n = 1); and severe wound infection (n = 1).
Age
The age of both participants in the trial conducted by Kenefick
2002# was 36 years, while in the trial conducted by Vaizey 2000#
the participants were aged 65 and 61 years. The mean age of the
participants in the trial carried out by Kahlke 2015# was 55.5
years (standard deviation (SD) = 11.8). The median age of the
participants in the trial conducted by Leroi 2005# was 57 years
(range 33 to 73 years). In the trial conducted by Sørensen 2010#
the median age of participants was 67 years (range 60 to 87 years).
In the trial conducted by Thin 2015 the mean age of participants
was 59 years (SD = 13 in the SNS group and 11 in the PTNS
group). In the trial conducted by Tjandra 2008 the median age of
the participants was 63.9 years (SD = 13.2) in the SNS arm and
63 years (SD = 12.1) in the control group. In the trial conducted
by Dinning 2015# the median age was 42 years (range 19 to 74
years).
Cause/type of faecal incontinence or constipation
The causes of faecal incontinence in the twoparticipants inVaizey’s
trial were, respectively, scleroderma and idiopathic degeneration
of the internal anal sphincter (Vaizey 2000#). The cause of faecal
incontinence cited in the trial conducted by Kahlke 2015# were
idiopathic (n = 8), anorectal surgery (n = 4), and neurogenic (n =
4). In the trial conducted by Leroi 2005# the majority of partici-
pants (22 of 34, 65%) suffered from urge incontinence, while four
suffered from passive incontinence and eight from mixed inconti-
nence. The causes of incontinence were reported as idiopathic (n
= 18); pudendal neuropathy (n = 14); postoperative internal anal
sphincter fragmentation (n = 1); and primary internal anal sphinc-
ter degeneration (n = 1) (Leroi 2005#). In the trial conducted by
Thin 2015 participants suffered from urge and passive inconti-
nence. In the trial conducted by Tjandra 2008 all participants had
both passive and urge incontinence. The participants in the trial
conducted by Kenefick 2002# suffered from severe resistant id-
iopathic constipation that had failed maximal conservative treat-
ment. The participants in the trial conducted by Dinning 2015#
suffered severe refractory idiopathic slow transit constipation. The
cause of faecal incontinence in the trial conducted by Sørensen
2010# was not stated. (See ’Characteristics of included studies’
table for details of the inclusion/exclusion criteria applied by each
trial).
Interventions
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The intervention in all eight trials consisted of SNS via a perma-
nently-implanted stimulator (Medtronic InterStim®).
In the trials conducted by Kenefick 2002#, Sørensen 2010#, and
Vaizey 2000#, the participants had received permanent implants
respectively 12 months, 12 months and 9 months previously.
• Kenefick 2002# reported that prior to permanent
implantation, both participants had undergone a successful
three-week trial of temporary percutaneous stimulation; whereas
Thin 2015, Tjandra 2008, and Leroi 2005# reported that before
permanent implantation, participants underwent temporary
percutaneous stimulation for, on average, 14 days, 10 days and
between 8 and 15 days respectively to assess their response to
treatment.
• Similarly, Kahlke 2015# reported that before permanent
implantation, participants underwent temporary percutaneous
stimulation for a period between 14 and 20 days to assess their
response to treatment.
• In the trial conducted by Dinning 2015#, following 3
weeks of temporary peripheral nerve evaluation all participants
underwent permanent SNS electrode implantation.
• In the trial conducted by Thin 2015, participants
underwent a trial of temporary SNS and participants with a
good response (at least 50% reduction in episodes of FI)
progressed to permanent stimulation.
• Also, in the trial conducted by Leroi 2005#, the decision to
progress from temporary to permanent stimulation was made on
the basis of at least a 50% reduction in the number of episodes of
incontinence per week, or a 50% reduction in the number of
faecal urgency episodes per week, or both.
• Similarly, in the trial conducted by Tjandra 2008 the
decision to progress to permanent stimulation was based on a
good response, defined as a 50% or greater reduction in faecal
incontinence episodes per week or a 50% or greater reduction in
number of days with faecal incontinence per week.
In the trial conducted by Kahlke 2015# and Leroi 2005# the
permanent pulse generator was placed in the upper outer part of
the buttocks. Similarly, in the trial conducted by Dinning 2015#
andTjandra 2008 the permanent pulse generator was placed in the
gluteal area. In the trial conducted by Vaizey 2000# it was placed
in the abdominal wall. Kenefick 2002# and Sørensen 2010# did
not report the location of the pulse generator.
Duration of treatment and follow up
The length of time between the participants receiving a perma-
nently-implanted stimulator and the start of the crossover period
varied from 3 weeks (Dinning 2015#), around 3 months (Kahlke
2015#; Leroi 2005#), through 9 months (Vaizey 2000#), to 12
months (Kenefick 2002#). In the trial carried out by Thin 2015
the follow-up time for the SNS and PTNS groups was six months.
In the trial conducted by Tjandra 2008, the follow up time for
the SNS group and the control group was 12 months.
In two trials the crossover period consisted of two two-week peri-
ods when the stimulator was either ’on’ or ’off ’, with no follow-
up (Kenefick 2002#; Vaizey 2000#). Similarly, in the third trial
the crossover period consisted of two one-week periods when the
stimulator was either ’on’ or ’off ’ with no follow-up (Sørensen
2010#); while in the fourth, larger, trial the crossover period con-
sisted of two one-month periods when the stimulator was ’on’ or
’off ’, with a three-month follow-up (Leroi 2005#). In the fifth trial
(Kahlke 2015#), the crossover period consisted of two three-week
periods when the stimulator was ’off ’ or ’on’, with a three-month
follow-up. In the sixth trial (Dinning 2015#), the crossover period
consisted, in the suprasensory phase, of two three-week periods
where the stimulator was on (suprasensory) or off (sham); long-
term follow-up is still ongoing.
Outcomes
The trials reported a variety of outcome measures.
Vaizey 2000# reported that participants used a diary to record
episodes of faecal incontinence for liquid or solid stool; anal
manometry was undertaken; and health status was assessed both
before permanent implantation and again at the beginning of the
trial, using an SF-36 questionnaire. In terms of anal manometry,
a stationary pull-through method was used with an eight-channel
perfused system, and the squeeze pressure was measured as the
incremental rise. Rectal sensation was tested using balloon disten-
sion with air (Vaizey 2000#).
Leroi 2005# reported that participants also used a diary, recording
episodes of faecal incontinence, faecal urgency, delay in postpon-
ing defaecation, and bowel movements. Severity of incontinence
was graded by the Cleveland Clinic Incontinence Scoring System,
while quality of life was assessed with the French version of the
American Society of Colon and Rectal Surgeons’ (ASCRS) Fe-
cal Incontinence Quality of Life Scale (FIQL). Anal manometry
was also undertaken (Leroi 2005#). Measurements of maximum
resting pressure and maximum squeeze pressure were recorded at
baseline, at the end of each crossover period, and at follow-up;
while rectal sensation to balloon distension with air was recorded
at baseline and at the end of the follow-up period (Leroi 2005#).
Kahlke 2015# reported outcomes that included frequency of
bowel movements, frequency of faecal incontinence, and the
Cleveland Clinic Incontinence Score (CCIS).
In the trial conducted byDinning 2015# participants used a bowel
diary (stool frequency per week; bowel motion per week; feeling
of complete evacuation per week; straining per week; laxative-free
days per week; soft stool per week; normal stool per week; hard
stool per week; pain score weekly average; bloating score weekly av-
erage; weekly global satisfaction score; weekly bothersome score).
Quality of life was documented using the SF-36 questionnaire.
Also, in the trial conducted by Thin 2015 participants utilised a
bowel diary to document the number and type of incontinence
episodes per week. Additionally, symptom severity was assessed
12Sacral nerve stimulation for faecal incontinence and constipation in adults (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
through the use of Cleveland Clinic Incontinence Score and qual-
ity of life was measured through use of Faecal Incontinence Qual-
ity of Life Scale (FIQL), Short Form 36 (SF-36) and EQ-5D.
Similarly, in the trial conducted byTjandra 2008 participants used
a bowel diary to record the number of incontinent episodes per
week; days with incontinence per week; days with staining per
week; and days with pads per week. Severity was scored by the
Wexner incontinence score (Cleveland Clinic Incontinence Scor-
ing System); and quality of life was evaluated by ASCRS’s FIQL,
and the standard Short Form-12 health survey quality of life ques-
tionnaire (SF-12) (Tjandra 2008).Measurements of anal manom-
etry (resting and squeeze pressure) were undertaken at baseline
for both SNS and control group, while further anal manometry
measurements were only carried out for the SNS group during
peripheral nerve evaluation and at 3-, 6- and 12-month follow-up
(Tjandra 2008).
In the trial conducted by Sørensen 2010#, outcomeswere reported
using bowel diaries and anal manometry.
In the trial conducted by Kenefick 2002#, outcomes included di-
ary-recorded bowel movements; the Wexner Constipation Score;
a symptom analogue score; anal manometry; and quality of life.
In terms of anal manometry, resting pressure was the maximal
anal resting pressure using a stationary pull-through technique,
and squeeze pressure was the maximal increment above resting
pressure. Threshold, urge and maximal tolerated volume were to
rectal balloon distension with air. Anal and rectal electrosensation
measured threshold sensation with increasing amplitude of stim-
ulation, recorded with a 1 cm bipolar ring electrode (5 Hz, 0.1 ms
and 10 Hz, 0.5 ms respectively) (Kenefick 2002#).
Timing of outcome measures
Four trials reported results at the end of the crossover pe-
riod (Dinning 2015#; Kenefick 2002#; Sørensen 2010#; Vaizey
2000#), while the trials by Kahlke 2015# and Leroi 2005# also
reported results at the end of a three-month follow-up after the
crossover period ended. The trial by Thin 2015 reported results
at baseline prior to intervention, at 3 months and 6 months fol-
low up. Tjandra 2008 reported results at the end of a 12-month
follow-up.
Excluded studies
See ’Characteristics of excluded studies’ table.
Risk of bias in included studies
The results of the methodological quality assessment along
with justifications are covered in the ’Risk of bias’ tables (see
’Characteristics of included studies’ table) for each trial and are
illustrated in Figure 2 and Figure 3.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
The information is provided in the ’Characteristics of included
studies’ table and presented visually in Figure 2 and Figure 3.
Random number generation
The method of randomisation was unclear in the trial conducted
byTjandra 2008.Thin 2015 randomised patients remotely using a
statistician uninvolved in recruitment: requests were made by and
actioned by email. Dinning 2015# utilised an off-site (NHMRC)
clinical trials centre automated phone link. Leroi 2005# and
Kahlke 2015# randomised participants by using a random num-
bers table. Similarly, Sørensen 2010# randomised participants us-
ing shuffling of envelopes but did not indicate how the envelopes
were filled. Kenefick 2002# and Vaizey 2000# provided no details
of the method for deciding which participants were initially allo-
cated to stimulator ’off ’ or ’on’.
Concealment of allocation
Five of the trials did not explicitly state that allocation was con-
cealed (Kahlke 2015#; Kenefick 2002#; Leroi 2005#; Sørensen
2010#; Vaizey 2000#). In the trial by Thin 2015 and Dinning
2015# randomisation and allocation was made remotely, hence
low risk of bias. The Tjandra 2008 trial, which used sealed en-
velopes, reported that the quality of allocation concealment was
at low risk of bias.
Blinding
In the trial carried out by Thin 2015, the outcome assessor was
blinded to participant allocation. The participants and the out-
come assessor were not blinded to the allocation in the trial con-
ducted byTjandra 2008. In the remaining six trials the participants
and outcome assessors were blinded to the allocation (Dinning
2015#; Kahlke 2015#; Kenefick 2002#; Leroi 2005#; Sørensen
2010#; Vaizey 2000#).
Incomplete outcome data
There were no withdrawals in three trials (Kenefick 2002#;
Sørensen 2010#; Vaizey 2000#). However, in the trial conducted
by Thin 2015, 9 participants out of the 40 enrolled withdrew
from the trial. Likewise, in the trial carried out by Leroi 2005#,
10 people out of the 34 enrolled prematurely discontinued the
trial. Furthermore, in the trial conducted by Kahlke 2015#, 2 par-
ticipants out of the 16 enrolled discontinued the trial. Similarly,
in the trial conducted by Tjandra 2008 seven participants in the
SNS group prematurely discontinued. In the trials conducted by
Kenefick 2002# and Vaizey 2000#, most of the outcome results
were reported for everyone who entered the trials. As the partic-
ipants were analysed in the groups to which they were originally
allocated, the analysis was effectively intention-to-treat. In the trial
carried out by Dinning 2015#, out of the 59 participants enrolled,
6 withdrew. The reasons for discontinuation were depression (n =
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1), too far to travel (n = 2), could not commit (n = 1), pregnancy
(n = 1) and severe wound infection (n = 1).
Selective reporting
Five trials were at low risk of bias as they reported all outcomes for
everyone (Dinning 2015#; Kahlke 2015#; Leroi 2005#; Tjandra
2008; Thin 2015); the others trials were unclear (see ’Risk of bias’
tables Figure 2; Figure 3).
Other potential sources of bias
None of the trials reported other sources of bias and so were judged
to be at low risk on this domain.
Effects of interventions
The eight trials, which comprised two parallel group trials (Thin
2015 and Tjandra 2008) and six crossover trials (Dinning 2015#,
Kahlke 2015#, Kenefick 2002#, Leroi 2005#, Sørensen 2010#,
and Vaizey 2000#), included 280 participants, of whom 177 re-
ceived a permanently-implanted stimulator.
Faecal incontinence
Six of these trials investigated the effects of SNS for faecal inconti-
nence (Kahlke 2015#; Leroi 2005#; Sørensen 2010#; Thin 2015;
Tjandra 2008; Vaizey 2000#).
1. Clinical outcomes (number cured and improved, episodes
of faecal incontinence, ability to defer defaecation, urgency,
incontinence score)
SNS versus control (medical therapy)
In the trial by Tjandra 2008 the SNS group experienced fewer
episodes of faecal incontinence compared to the control group
who received optimal medical therapy
• both at 3 months (MD −5.20, 95% CI −9.15 to −1.25,
Analysis 1.1.1)
• and 12 months (MD −6.30, 95% CI −10.34 to −2.26,
Analysis 1.1.2),
In addition, SNS was better than control in terms of:
• Number of days of pad use per week (MD −1.40, 95% CI
−2.59 to −0.21 at 3 months, Analysis 1.2.1; though this was no
longer statistically significant at 12 months, MD −1, 95% CI
−2.13 to 0.13, Analysis 1.2.2);
• Cleveland Clinic Incontinence Score (MD −11, 95% CI
−11.60 to −10.40 at 3 months; and MD −12.90 to −13.58 to
−12.22, Analysis 1.5).
Additionally, none of the participants in the SNS group had wors-
ening of faecal incontinence, with 25 participants (47.2%) achiev-
ing continence, but the data for the control group were not re-
ported (Tjandra 2008).
SNS versus PTNS
In the trial carried out by Thin 2015 the SNS group experienced
fewer episodes of faecal incontinence compared to the PTNS
group:
• both at 3 months (MD −3.00, 95% CI −6.61 to 0.61,
Analysis 2.1.1)
• and 6 months (MD −3.20, 95% CI −7.14 to 0.74,
Analysis 2.1.2).
Additionally, SNSwas better thanPTNSwith regards toCleveland
Clinic Incontinence Score:
• both at 3 months (MD −1.70, 95% CI −5.14 to 1.74,
Analysis 2.2.1)
• and 6 months (MD −3.00, 95% CI −6.74 to 0.74,
Analysis 2.2.2).
Additionally, at the six months follow-up three participants in the
SNS group and PTNS group reported no episodes of faecal incon-
tinence. Moreover, in the SNS group 10 participants had a 50%
or greater reduction in episodes of faecal incontinence compared
with 7 participants in the PTNS group (Thin 2015).
Faecal incontinence: crossover trials
In the trial conducted by Vaizey 2000#, during the period when
the stimulator was ’off ’ the participants experienced an average
of six episodes of faecal incontinence per week, compared with
an average of one episode per week when the stimulator was ’on’
(Analysis 3.2). SNS resulted in one participant being cured and
the other experiencing a reduction in the number of episodes of
faecal incontinence per week from 10 when the stimulator was
’off ’ to one when it was ’on’ (Analysis 3.1).
In the trial conducted by Leroi 2005#, at the end of the crossover
period and while still blinded, the participants chose the period
of stimulation (’on’ or ’off ’) they had preferred and the mode of
stimulation corresponding to the selected period (’on’ or ’off ’)
was then continued for the three-month follow-up period. Most
outcomes at baseline, prior to the crossover, during the ’on’ and
’off ’ periods of the crossover and at follow-up were reported sep-
arately for the group of 19 participants who preferred the ’on’ pe-
riod and for the group of 5 participants who preferred the ’off ’
period once the crossover period had ended. For the group of 19
participants, during the one-month period when the stimulator
was ’off ’ the median (range) number of episodes of faecal incon-
tinence per week was 1.7 (0 to 9) compared with 0.7 (0 to 5)
during the ’on’ period (Analysis 3.2; P < 0.05), with 0.5 (0 to
11) episodes per week during the three-month follow-up period.
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During the follow-up period 5 (26%) of the 19 participants were
cured (no episodes of faecal incontinence) and 17 (89%) felt they
had improved (Analysis 3.1). The median (range) minutes delay
in postponing defaecation was 1.4 (1 to 3) during the ’off ’ period,
compared with 1.8 (1 to 3) during the ’on’ period, and 1.9 (1 to 3)
during the follow-up period (Analysis 3.3). The median (range)
episodes of urgency per week were 1.4 (0 to 19) during the ’off ’
period compared with 1 (0 to 16) during the ’on’ period and 1 (0
to 24) during the follow-up period (Analysis 3.4).
The group of five participants who chose the ’off ’ period once the
crossover period had ended actually experienced an increase in the
number of episodes of faecal incontinence when the stimulator was
’on’ compared with when it was ’off ’. For this group, the median
(range) number of episodes of faecal incontinence per week was
1.7 (0 to 11) during the one-month ’off ’ period compared with
3.7 (0 to 11) during the one-month ’on’ period and 3.5 (0 to
10) during the three-month follow-up period (Analysis 3.2). The
median (range)minutes delay in postponing defaecation remained
relatively unchanged at 1 (1 to 3) during the ’off ’ period compared
with 1 (1 to 2) during the ’on’ period, and 1.2 (1 to 1.8) during
the follow-up period (Analysis 3.3). The median (range) episodes
of urgency per week were 4.5 (3 to 10) during the ’off ’ period
compared with 8.2 (2 to 19) during the ’on’ period and 5.2 (0 to
20) during the follow-up period(Analysis 3.4) (Leroi 2005#).
The Cleveland Clinic Incontinence Score ranges from 0 (nor-
mal continence) to 20 (total incontinence). In the trial conducted
by Leroi 2005#, for the whole group of participants the median
(range) Cleveland Clinic Incontinence Score was 10.5 (4 to 17)
during the ’off ’ period compared with 8.5 (3 to 18) during the
’on’ period (Analysis 3.6). For the follow-up period, the Cleveland
Clinic Incontinence Score was not reported for the whole group,
but separately for the group of 19 who had chosen the ’on’ period
and for the group of 5 who had chosen the ’off ’ period following
the crossover. For the group of 19, themedian score for the follow-
up period was 10 (3 to 17) while for the group of 5 it was 13 (11
to 18) (Analysis 3.6) (Leroi 2005#).
In the trial carried out by Kahlke 2015#, at the end of the crossover
while still blinded all patients (n = 14) elected to continue with
’on’ as their preferred intervention for the final 3 months (final
period). FI episodes per week were at a low level (average of 1
(SD = 1.7)) during the ’on’ period, but increased significantly (P <
0.05) on average to 8.4 (SD = 8.7) during the ’off ’ period. During
the final period FI episodes per week remained low 0.3 (SD =
0.5) (Analysis 3.2). The CCIS was significantly higher (P < 0.05)
during the ’off ’ period (14.6 (SD = 4.6)) compared with the ’on’
period (8.7 (SD = 3.6)). During the final period the CCIS was
6.4 (SD = 3.3) (Analysis 3.6). The overall number of defaecations
per week also declined significantly (P < 0.05) in the crossover ’on’
period (10.9 (SD = 4.1)) compared with the ’off ’ period (18.2
(SD = 8.7)). Furthermore, during the final period the number of
defaecations per week was 9.4 (SD = 2.6) (Analysis 3.12).
In the trial conducted by Sørensen 2010# there were no faecal
incontinence episodes per week in both the ’on’ and ’off ’ peri-
ods (Analysis 3.2). The mean episodes of urgency per week was
4.14 (−0.16 to 8.44) during the ’off ’ period and reduced to 2.43
(−0.23 to 5.1) during the ’on’ period (Analysis 3.4) (Sørensen
2010#).
Tjandra 2008 did not report urgency or use of anal plugs. Vaizey
2000# did not report urgency, the ability to defer defaecation, or
incontinence score. Sørensen 2010# did not report number cured
or improved, ability to defer defaecation, and incontinence score.
Of the Vaizey 2000#, Thin 2015, Sørensen 2010#, and Leroi
2005# trials, none reported the use of pads, anal plugs or the need
for further treatment during follow-up.
2. Quality of life outcomes
Tjandra 2008 used the SF-12 and ASCRS FIQL quality of life
indexes. SF-12 is developed from the longer SF-36 and gener-
ates eight scale scores which can be summarised into a physical
and mental summary score. Both of these physical and mental
scores have a range from 0 to 100, higher scores indicating bet-
ter quality of life. ASCRS FIQL index comprises 29 questions
that are grouped into four sections: lifestyle; coping/behaviour; de-
pression/self-perception; and embarrassment. The ASCRS FIQL
scores range from one (worst) to five (best). Vaizey 2000# used
the SF-36 tool, while Leroi 2005# used the French version of the
ASCRS FIQL. Thin 2015 used the ASCRS FIQL, SF-36 and EQ-
5D. EQ-5D, a standardised instrument for use as a measure of
health outcome, provides a descriptive profile and a single index
value for health status.
SNS versus medical treatment
In the trial by Tjandra 2008 the SNS group reported better quality
of life on FIQL index scores in all four scales compared to the
control group in terms of:
1. Lifestyle
• 3 months (MD −1.22, 95% CI −1.52 to −0.92)
• 12 months (MD −1.00, 95% CI −1.30 to −0.70, Analysis
1.8)
2. Coping behaviour
• 3 months (MD, −1.02, 95% CI −1.34 to −0.70)
• 12 months (MD, −0.82, 95% CI −1.14 to −0.50,
Analysis 1.9)
3. Depression/self-perception
• 3 months (MD, −0.63, 95% CI −0.89 to −0.37)
• 12 months (MD, −0.61, 95% CI −0.91 to −0.31,
Analysis 1.10)
4. Embarrassment
• 3 months (MD, −1.19, 95% CI −1.47 to −0.91)
• 12 months (MD, −0.98, 95% CI −1.28 to −0.68,
Analysis 1.11)
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However, there were no significant differences between the two
groups on the generic quality-of-life scores at 3 or 12 months
for either the SF-12 Physical health scale (MD, −1.68, 95% CI
−5.70 to 2.34 at 3 months; MD, −1.72, 95% CI −5.31 to 1.87
at 12 months, Analysis 1.6); or SF-12 Mental health scale (MD,
−2.34, 95% CI −6.23 to 1.55 at 3 months; MD, −1.00, 95%
CI −4.89 to 2.89 at 12 months, Analysis 1.7).
SNS versus PTNS
In the trial carried out by Thin 2015 the SNS group reported
no statistically significant differences in quality of life FIQL index
scores in all four domains compared with the PTNS group in
terms of:
1. Lifestyle
• 3 months (MD, −0.20, 95% CI −0.82 to 0.42)
• 6 months (MD, −0.20, 95% CI −0.82 to 0.42, Analysis
2.3)
2. Coping
• 3 months (MD, −0.20, 95% CI −0.72 to 0.32)
• 6 months (MD, −0.50, 95% CI −1.09 to 0.09, Analysis
2.4)
3. Depression
• 3 months (MD, 0.10, 95% CI −0.46 to 0.66)
• 6 months (MD, −0.10, 95% CI −0.66 to 0.46, Analysis
2.5)
4. Embarrassment
• 3 months (MD, −0.30, 95% CI −0.82 to 0.22)
• 6 months (MD, −0.60, 95% CI −1.16 to −0.04, Analysis
2.6)
However, EQ-5D scores were not significantly different between
the two groups (at three months MD, 0.06, 95% CI −0.17 to
0.29; at six months MD, 0.13, 95% CI −0.08 to 0.34, Analysis
2.7).
Faecal incontinence: crossover trials
Rawdata for the SF-36was unavailable, but was reported as within
patient changes (from baseline to three months and six months
respectively). Increases in physical role was seen for SNS (at six
months: 25.0 versus 0.0, SNS and PTNS respectively, Analysis 3.7
), while modest increases were observed for emotional role (at six
months: 17.8 versus 16.7, SNS and PTNS respectively, Analysis
3.7 ) and social functioning (at six months: 17.5 versus 10.9, SNS
and PTNS respectively, Analysis 3.7) for both interventions.
Vaizey 2000# reported quality of life before implantation of
the stimulator and nine months after implantation, prior to the
crossover period. There was an overall improvement in both par-
ticipants but especially so in one participant in terms of the do-
mains of bodily pain (30 versus 100); role-physical (0 versus 100);
social function (12 versus 100); and vitality (10 versus 80) Analysis
3.7. Leroi 2005# recorded quality of life using the French version
of the FIQL instrument at baseline and again during the final
three-month follow-up period, noting a statistically significant (P
< 0.05) improvement in themedian scores for all domains: lifestyle
(1.7 versus 3.2); coping/behaviour (1.5 versus 2.7); depression/
self-perception (2.2 versus 3.6); and embarrassment (1.3 versus
2.3) Analysis 3.9.
Sørensen 2010# and Kahlke 2015# did not report quality of life
of participants.
3. Surrogate measures (anorectal manometry)
Tjandra 2008 reported anal manometry for both groups at base
line and only the SNS group during the follow-up period. There
was a non-significant (P > 0.05) change in the two parameters
reported. In the SNS group the mean resting pressure (cm H O)
was 40.4 (SD = 15.9) at baseline and 40.9 (SD = 21.9) at 12
months, Analysis 3.11. Similarly, in the SNS group the mean
squeeze pressure (cmH O) was 83.2 (SD = 39.6) at baseline and
90.2 (SD = 54.9) at 12 months (Tjandra 2008), Analysis 3.11.
Moreover, in the trial conducted by Sørensen 2010#, the mean
(95% CI for mean) resting anal pressure (cm H O) decreased
from 84.2 (70.4 to 98.3) when the stimulator was ’on’ to 106.2
(71.1 to 141.4) when the stimulator was ’off ’, Analysis 3.11.How-
ever, the mean values for squeeze pressure remained the same dur-
ing the ’on’ and ’off ’ periods: 223.0 (159.1 to 287.0) and 223.0
(153.7 to 292.4) respectively, Analysis 3.11.With regards to rectal
sensory threshold (ml), the mean (95% CI for mean) threshold
sensation was 50.0 (34.6 to 65.4) during the ’off ’ period which de-
creased to 27.1 (17.8 to 36.4)when ’on’; with corresponding values
for urge of 82.9 (64.8 to 101) and 60 (48.7 to 71.3), Analysis 3.11.
Contrastingly, mean maximum-tolerated volume (ml) remained
the same during the ’off ’ and ’on’ periods: 124 (106 to 142) and
124 (82.4 to 165.6) respectively (Sørensen 2010#), Analysis 3.11.
In the trial conducted by Vaizey 2000# the mean (range) resting
anal pressure (cm H O) improved from 43 (35 to 50) when the
stimulator was ’off ’ to 58 (45 to 70) when it was ’on’; with the
corresponding values for squeeze pressure also improving from 65
(60 to 70) to 95 (90 to 100), Analysis 3.11. In terms of rectal
sensation to distention (ml), the mean (range) threshold sensation
was 38 (25 to 50) during the ’off ’ period compared with 68 (45 to
90) during the ’on’ period, with corresponding values for urge of
85 (70 to 100) and 103 (85 to 120); and, for maximum-tolerated
volume, 135 (120 to 150) during the ’off ’ period compared with
140 (130 to 150) during the ’on’ period, Analysis 3.11.
Leroi 2005# reported anorectal manometry measures separately
for the group of 19 participants who preferred the ’on’ period and
for the group of five participants who preferred the ’off ’ period
following the crossover. For the group of 19, the median (range)
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maximum resting pressure (cm H O) improved from 37 (26 to
100) during the one-month period when the stimulator was ’off ’
to 50 (27 to 155) when it was ’on,’ Analysis 3.11. The median
(range) maximum squeeze pressures improved from 49 (10 to 98)
during the ’off ’ period to 53 (6 to 326) during the ’on’ period,
Analysis 3.11. The median (range) threshold, constant sensation
volume and maximum tolerated volume (all ml) were reported
only for baseline and the final three-month follow-up period fol-
lowing crossover. Threshold values were 25 (10 to 120) at baseline
compared with 30 (10 to 120) during the follow-up period, with
the corresponding values for constant sensation volume of 100
(40 to 230) and 85 (30 to 300), while maximum tolerated volume
was 185 (80 to 350) at baseline compared with 170 (40 to 275)
at follow-up, Analysis 3.11.
For the group of five participants who preferred the ’off ’ period
following the crossover period, themedian (range) maximum rest-
ing pressure (cm H 0) improved from 50 (39 to 98) during the
’off ’ period to 64 (37 to 98) during the ’on’ period (Leroi 2005#),
Analysis 3.11. However, the median (range) maximum squeeze
pressures (cm H 0) decreased from 54 (37 to 110) during the
’off ’ period to 30 (21 to 90) during the ’on’ period, Analysis 3.11.
The median (range) rectal volume sensation values (ml) remained
relatively unchanged between baseline and follow-up, with thresh-
old values 10 (10 to 40) at baseline and 10 (10 to 50) during fol-
low-up; constant sensation volume 50 (20 to 90) at baseline and
50 (20 to 95) at follow-up; and maximum tolerated volume 200
(80 to 300) at baseline compared with 195 (100 to 300) at follow-
up (Leroi 2005#), Analysis 3.11.
Thin 2015 andKahlke 2015# did not report anorectal manometry
outcomes.
4. Adverse effects
Faecal incontinence: SNS versus medical treatment
In the trial conducted by Tjandra 2008, adverse events reported
for the SNS group consisted of implantation site pain (6%), par-
ticularly in slimmer participants; seroma (2%), which required
percutaneous aspiration; and excessive tingling in the vaginal re-
gion (9%).
Faecal incontinence: SNS versus PTNS
In the trial carried out by Thin 2015, adverse events reported for
the SNS group include mild ipsilateral leg pain during temporary
testing (n = 1) and stimulator-site pain following insertion of neu-
rostimulator (n = 2).
Faecal incontinence: crossover trials
Leroi 2005# reported that, of 27 participants receiving a perma-
nent implant, 4 (15%) experienced adverse events prior to the
commencement of the crossover period, resulting in explantation
of the stimulator. Three of the explantations were due to unre-
solved pain and one was for recurrent infection. Another partici-
pant suffered an adverse event (stroke), not related to SNS, prior
to the crossover period. Leroi 2005# did not report whether there
had been any adverse events during the crossover period or three-
month follow-up period. Vaizey 2000# and Sørensen 2010# did
not report whether any adverse events had occurred during the
course of the trial.
In the trial carried out by Kahlke 2015#, adverse events re-
ported for the enrolled participants after implantations included:
haematoma formation (n = 3), misplacement of tined lead (1),
and pain at stimulator site (n = 1).
5. Health economics
None of the trials (Kahlke 2015#; Kenefick 2002#; Leroi 2005#;
Sørensen 2010#; Thin 2015; Tjandra 2008; Vaizey 2000#) pro-
vided any information on costs within the trials.
6. Other outcomes quoted by trial authors and judged to be
important
Leroi 2005# reported bowel movements per week; and regard-
ing anorectal manometry, reported squeeze pressure duration (sec-
onds) and constant sensation volume (ml). For the 19 participants
who preferred the ’on’ period once the crossover period had ended,
during the one-month period when the stimulator was ’off ’ the
number of bowel movements per week was 10.6 (6 to 33) com-
pared with 10.2 (5 to 26) during the ’on’ period, and 10.6 (7 to
37) during the follow-up period, Analysis 3.12. For the group of
five participants who preferred the ’off ’ period once the crossover
period had ended, the number of bowel movements per week dur-
ing the ’off ’ period was 12.7 (8 to 19) compared with 11.2 (7 to
32) during the ’on’ period, and 11.7 (7 to 32) during the follow-
up period, Analysis 3.12. For the group of 19 participants, squeeze
pressure duration was 21 (4 to 32) seconds during the ’off ’ pe-
riod compared with 18 (6 to 92) during the ’on’ period; the cor-
responding values for the group of five participants were 40 (5 to
40) during the ’off ’ period compared with 32 (23 to 38) during
the ’on’ period, Analysis 3.11. For the group of 19 participants,
the median (range) constant sensation volume values for baseline
were 100 (40 to 230) compared with 85 (30 to 300) during the
follow-up period; the corresponding values for the group of five
participants remained relatively unchanged at 50 (20 to 90) at
baseline and 50 (20 to 95) at follow-up, Analysis 3.11.
Sørensen 2010# reported mean (95% CI for mean) soiling per
week for the participants which decreased from1.86 (0.29 to 3.43)
during the ’off ’ period to 0.71 (−0.69 to 2.11) during the ’on’
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period, Analysis 3.13. Sørensen 2010# also reported mean (95%
CI for mean) bowel movements per week which reduced from
12.1 (6.32 to 17.9) during the ’off ’ period to 8.86 (6.21 to 11.5)
during the ’on’ period, Analysis 3.12. Similarly, themean (95%CI
for mean) passive leakage per week reduced from 0.43 (−0.41 to
1.27) during the ’off ’ period to 0 during the ’on’ period, Analysis
3.16.
Moreover, Tjandra 2008 reported dayswith incontinence anddays
with staining per week. SNS was better than control in terms of:
• Number of days with faecal incontinence per week (MD
−1.90, 95% CI −2.66 to −1.14 at 3 months; and MD −2.10,
95% CI −3.01 to −1.19 at 12 months, Analysis 1.3);
• Number of days with faecal staining per week (MD −3.20,
95% CI −3.90 to −2.50 at 3 months; and MD −3.10, 95% CI
−3.89 to −2.31 at 12 months, Analysis 1.4);
Constipation
Twocrossover trials investigated the effects of SNS for constipation
(Dinning 2015#; Kenefick 2002#).
1. Number improved, bowel movements, percentage time
with abdominal pain and bloating, constipation score
In the trial conducted by Dinning 2015#, during the period when
the stimulator was turned off (sham) the participants on average
had stool frequency of 6.4 compared with an average of 6.6 when
the stimulator was turned on (Analysis 4.6).With regards to bowel
movements per week, this was on average 4.0 during the off pe-
riod compared with 4.3 during the on period, Analysis 4.1. Fur-
thermore, on average the pain score per week was 1.0 during the
on period compared with 0.9 during the off period, Analysis 4.7.
Bloating score on average per week was 1.2 in both the ’off ’ and
’on’ periods, Analysis 4.8.
In the trial conducted by Kenefick 2002#, both participants ex-
perienced an improvement, both in terms of bowel movements
per week and the percentage of time with abdominal pain and
bloating, Analysis 4.1, Analysis 4.2. During the period when the
stimulator was ’off ’ the participants experienced an average of
two bowel movements (episodes of defaecation) per week, com-
pared with five when the stimulator was ’on’, an increase of 150%
(Kenefick 2002#), Analysis 4.1. The average percentage of time
with abdominal pain and bloating was 79% during the ’off ’ pe-
riod compared with 33% during the ’on’ period, Analysis 4.2.
The Wexner constipation score ranges from 0 (normal) to 30 (se-
vere constipation). The mean (range) scores for the participants
improved from 14 (13 to 15) during the ’off ’ period to 9 (5 to 13)
during the ’on’ period, Analysis 4.3. Kenefick 2002# also noted an
improvement in symptoms with the Symptom Analogue Score,
with mean (range) scores during the ’off ’ period of 32 (30 to 33),
compared with scores of 74 (60 to 88) during the ’on’ period,
Analysis 4.4. Dinning 2015# did not report constipation scores.
2. Quality of life
Kenefick 2002#, using the SF-36 tool, reported a marked im-
provement in both participants after a year of chronic stimulation
compared with baseline, although no data were provided. Dinning
2015# utilised the SF-36 tool; however no significant changes in
the quality-of-life scores were reported, Analysis 4.9.
3. Surrogate measures (anorectal manometry)
In the trial conducted by Kenefick 2002#, the mean (range) max-
imal resting pressures (cm H 0) improved from 51 (39 to 63)
when the stimulator was ’off ’ to 76 (68 to 84) when it was ’on’,
with the corresponding values for maximal squeeze pressures also
improving from 54 (51 to 57) during the ’off ’ period to 93 (41
to 145) during the ’on’ period, Analysis 4.5. In terms of threshold
sensation (ml air), the mean (range) values were 35 (30 to 40) dur-
ing the ’off ’ period compared with 18 (15 to 20) during the ’on’
period; while the corresponding figures for urgency were 70 (60
to 80) compared with 34 (33 to 35); and for maximum-tolerated
volumes, 103 (85 to 120) during the ’off ’ period compared with
68 (65 to 70) during the ’on’ period, Analysis 4.5. Dinning 2015#
did not report anal manometry.
4. Adverse effects
Kenefick 2002# reported that there were no adverse events during
the course of the trial. Dinning 2015# reported 73 adverse events,
which includes pain at site of the implanted pulse generator (32),
wound infection (12) and urological symptoms (17), Analysis
4.10.
5. Health economics
Kenefick 2002# and Dinning 2015# provided no information on
costs.
D I S C U S S I O N
Summary of main results
The finding of this review is that SNS for faecal incontinence can
significantly improve faecal continence in some selected people,
bearing in mind the limited evidence from randomised controlled
trials.
On the other hand, we found that SNS did not seem to improve
symptoms in people with constipation, but there were only two
randomised trials providing evidence, of which one trial had only
two participants.
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Only eight trials, comprising two parallel group trials (Thin
2015; Tjandra 2008), and six small crossover trials were identified
that met our inclusion criteria (Dinning 2015#; Kahlke 2015#;
Kenefick2002#; Leroi 2005#; Sørensen2010#;Vaizey 2000#). Six
of these trials focused on SNS for faecal incontinence (FI) (Kahlke
2015#; Leroi 2005#; Sørensen 2010#; Thin 2015; Tjandra 2008;
Vaizey 2000#), while two assessed the effects of SNS for consti-
pation (Dinning 2015#; Kenefick 2002#). Two of the trials each
contained only two participants (Kenefick 2002#; Vaizey 2000#);
while the trial by Sørensen 2010# enrolled seven participants, and
Kahlke 2015# enrolled 16 participants. Although still relatively
small, the trial by Leroi 2005# enrolled 34 participants; and Thin
2015 enrolled 40 participants. For constipation, Dinning 2015#
enrolled 59 participants; whilst for FI, Tjandra 2008 enrolled 120
participants, making them the largest of the trials that were in-
cluded.
Faecal incontinence
The trials conducted by Vaizey 2000# and Leroi 2005# suggest
that for some selected participants, SNS can reduce episodes of
faecal incontinence and urgency and improve the ability to defer
defaecation, leading to a better quality of life. However, a minority
may get worse despite apparently successful testing before perma-
nent implantation. Sørensen 2010# found that SNS can reduce
number of defaecations, urgency episodes, soiling and passive leak-
age, while increasing first sensation of content in the rectum. Sim-
ilarly, Kahlke 2015# found that SNS significantly reduces faecal
incontinence episodes and bowel movements and improves CCIS
scores. Furthermore, the trial by Tjandra 2008 suggests that sacral
nerve stimulation in selected participants with severe faecal incon-
tinence can significantly reduce episodes of faecal incontinence as
well as improving the ability to defer defaecation but this did not
quite result in measurable improvement in quality of life. Addi-
tionally, the trial by Thin 2015 found that in the short term SNS
provides some clinical benefit to patients with FI.
In the trial by Leroi 2005#, at the end of the crossover period and
while still blinded, the participants chose the period of stimula-
tion (’on’ or ’off ’) they had preferred and the mode of stimula-
tion corresponding to the selected period (’on’ or ’off ’) was then
continued for the 3-month follow-up. Rather than reporting out-
comes for the trial group as a whole, Leroi 2005# reported most
outcomes (at baseline; prior to the crossover period; during the
’on’ and ’off ’ crossover periods; and at follow-up) separately for
the group of 19 participants who preferred the ’on’ period and the
group of 5 who preferred the ’off ’ period. The characteristics of
the two groups differed somewhat in terms of type and duration
of faecal incontinence. The two groups responded differently to
SNS, with the group of 19 reporting a 59% reduction in episodes
of faecal incontinence per week, from a median of 1.7 during the
’off ’ period to 0.7 during the ’on’ period. In contrast, the group
of five experienced a 118% increase in episodes of faecal inconti-
nence per week: from a median of 1.7 during the ’off ’ period to
3.7 during the ’on’ period.
If results for the ’on’ and ’off ’ periods of the crossover had been
reported for the trial group as a whole then in terms of episodes
of faecal incontinence per week, ability to defer defaecation, and
episodes of urgency, SNS would have been shown to be less ef-
fective compared with the results for the group of 19 participants
who preferred the ’on’ period. The fact that five participants chose
the mode of stimulation corresponding to the ’off ’ period at the
end of the crossover emphasises the fact that SNS for faecal incon-
tinence is not an effective treatment for all patients eligible for the
procedure, even taking into account that temporary percutaneous
stimulation for a two- to three-week period prior to permanent
implantation allows selection of those for whom permanent SNS
is likely to be effective. Despite having met the criteria to progress
from temporary to permanent stimulation (at least a 50% reduc-
tion in the number of episodes of faecal incontinence per week
or a 50% reduction in the number of episodes of faecal urgency
per week, or both) these five participants actually experienced an
increase rather than a reduction in episodes of faecal incontinence
during the ’on’ period compared with the ’off ’ period.
Adverse effects
Vaizey 2000# and Sørensen 2010# did not report adverse effects.
However, the other four trials did (Kahlke 2015#; Leroi 2005#;
Thin 2015; Tjandra 2008). Leroi 2005# reported a relatively high
adverse event rate, with 4 (15%) of the 27 participants who re-
ceived a permanent implant experiencing an adverse event re-
quiring removal (explantation) of the stimulator, all prior to the
crossover period. Three of the explantations were because of un-
resolved pain, while the fourth was because of recurrent infection.
These adverse events were resolvable through removal of the de-
vice, and no adverse events appeared to have occurred during the
second crossover period or follow-up period. In the trial conducted
by Tjandra 2008, adverse events included pain at the site of im-
plantation, seroma which required percutaneous aspiration, and
excessive tingling in the vaginal region. However, no septic com-
plication requiring explantation or urinary/sexual function-related
adverse events were reported (Tjandra 2008). Also, in the trial car-
ried out by Thin 2015, adverse effects included mild ipsilateral leg
pain during temporary testing which resolved after removal of the
temporary lead and insertion of the permanent implant. Other
adverse events experienced include stimulator-site pain following
insertion of the neurostimulator, which resolved with adjustment
of stimulator settings (Thin 2015). Finally, in the trial conducted
by Kahlke 2015#, adverse events reported for the enrolled partic-
ipants after implantations included: haematoma formation (n =
3), misplacement of tined lead (n = 1) and pain at stimulator site
(n = 1).
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Constipation
In the trial of only two participants conducted by Kenefick 2002#
assessing the effects of SNS for constipation, bowel movements
per week were increased by 150%, while the time with abdominal
pain and bloating decreased from 79% during the ’off ’ period
to 33% during the ’on’ period; the Wexner constipation score
showed an improvement of 36%. The much larger RCT of 59
participants carried out by Dinning 2015# found that in patients
with refractory slow transit constipation, SNS did not improve
the frequency of complete bowel movements per week.
Adverse effects
Dinning 2015# reported 73 adverse events which included pain
at the site of the implanted pulse generator (32), wound infection
(12), and urological symptoms (17). Kenefick 2002# reported that
no adverse effects had occurred.
Overall completeness and applicability of
evidence
This systematic review includes eight trials, all of which are RCTs.
Six assessed SNS for faecal incontinence (219 participants enrolled
overall) while two trials assessed SNS for constipation (61 partic-
ipants enrolled). In the interval since the first Cochrane review
on this subject (Mowatt 2007), SNS has become well established
as first-line minimally-invasive treatment for patients with FI fail-
ing conservative measures, with recognition of this fact by regula-
tory agencies (FDA 1998; NICE 2007). Such widespread accep-
tance has been based almost exclusively on post-registration data
published in the form of numerous case series, including some
large well-designed prospective non-randomised studies (Wexner
2010).
The availability of data from randomised trials has progressed
slightly with five new trials being added to this update (Dinning
2015#; Kahlke 2015#; Sørensen 2010#; Thin 2015; Tjandra
2008). Within the included trials, potentially relevant primary
outcome measures (such as the proportion of participants either
cured or improved, having urgency, and using pads/plugs) were
not reported consistently. Other primary outcome measures such
as incontinence scores and quality-of-life scores were also not con-
sistently reported. This variation has made comparison between
the trials problematic. The addition of these trials does not change
the conclusions reached in the previous review and provides fur-
ther evidence for a reduction in episodes of faecal incontinence
and urgency, and improvement in the ability to defer defaecation.
Surrogate outcome measures
Anorectal manometry measurements, although commonly re-
ported in trials, does not appear to provide information that can
be used to determine which patients will benefit from SNS, and
so does not appear to provide clinically useful information.
Quality of the evidence
In terms of methodological quality, the main uncertainty in judg-
ing trial bias stemmed from lack of clarity around randomisation
techniques and allocation concealment. Additionally, participant
blinding in the trials is complicated by the widely-acknowledged
preference of the majority of participants for suprasensory stimu-
lation (meaning that the current needs to be so high to be effective
that the patient is aware of it) whichmakes allocation concealment
and use of valid sham therapy problematic. Hence the observed
effect may have been overestimated due to a placebo effect.
Moreover, some trials had little or no wash-out period between the
two crossover periods with short treatment duration, thus carry-
over effects when the device was used first in the ’on’ position may
exist.
Another methodological limitation is the heterogeneity in the
collection of data and method of analysis: some trials reported
outcomes at specific time points whereas others reported average
outcome for the whole cohort with an average follow-up period.
Hence formal statistical synthesis was generally not possible due
to the heterogeneity in reported outcomes and styles of reporting,
as well as differences in the populations, interventions and trial
designs.
Some of the trials included in this review had a small sample of
participants which would affect estimates of treatment differences.
Furthermore, follow-upperiodwas generally inadequate andneeds
to be longer to further evaluate long-term effects of SNS.
Agreements and disagreements with other
studies or reviews
Faecal incontinence
Our findings that SNS for faecal incontinence can significantly
improve faecal continence in some selected patients is in agree-
ment with an earlier systematic review conducted in the UK of the
efficacy and safety of SNS for faecal incontinence by Fraser 2004.
This was submitted to the National Institute for Health and Clin-
ical Excellence (NICE) Interventional Procedures Programme in
2004 as part of NICE’s consideration of this topic (Fraser 2004).
The systematic review conducted by Fraser 2004 included one trial
that is also included in this review (the crossover trial conducted
by Vaizey 2000#), a non-randomised multicentre trial involving
37 participants, and six case series enrolling 266 participants, of
whom149 received permanent implants. The review reported that
41% to 75% of participants achieved complete faecal continence
and 75% to 100% experienced an improvement of 50% or more
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in the number of faecal incontinence episodes. In the multicen-
tre trial and all six case series, SNS resulted in a decrease in the
number of episodes of faecal incontinence per week (see Table 1)
(Fraser 2004). The review also noted a relatively high adverse event
rate: amongst 149 participants receiving permanent implants in
the case series, 19 (13%) adverse events were reported, although
these resulted in the explantation of only four devices. Amongst
34 participants receiving permanent implants in the multicentre
trial, 15 (44%) adverse events were reported, resulting in the re-
moval of two devices.
Our findings that SNS for faecal incontinence can significantly
improve faecal continence in some selected patients is also in agree-
ment with a systematic review conducted in the UK of clinical ef-
fectiveness of neuromodulation in the treatment of faecal inconti-
nence by Thin 2013. This systematic review for SNS included 61
eligible studies of which the majority were prospective case series
(n = 50) and only two were randomised clinical trials. The two
randomised trials were the parallel-group study by Tjandra 2008
and the crossover study by Leroi 2005#, both included in our cur-
rent systematic review. The review reported the success rates for
SNS (based on at least 50% improvement in FI episodes per week)
were 63% (range 33% to 36%), 58% (range 52% to 81%) and
54% (range 50% to 58%) in the short, medium and long term
respectively. Furthermore, 36% (range 8% to 68%), 32% (range
4% to 74%) and 20% (range 2% to 48%) of participants achieved
complete faecal continence.
Similarly, a meta-analysis conducted by Tan 2011 was in agree-
ment with our findings. In their review 34 studies were included of
which the majority (n = 28) were prospective non-randomised tri-
als (Tan 2011). The remaining studies included three randomised
control trials. Two of the RCTs were crossover trials (Leroi 2005#;
Vaizey 2000#), while the third was a parallel-group trial (Tjandra
2008): all are included in the current review. Tan and colleagues
foundSNS significantly improved the faecal incontinence episodes
per week (weighted mean difference −6.83; 95% confidence in-
terval −8.05 to −5.60; P < 0.001) compared with maximal con-
servative therapy (Tan 2011). Additionally, the adverse events rate
reported was 15% for permanent SNS, 3% resulting in permanent
explantation.
Constipation
The systematic review by Jarrett 2004 included two case series in-
volving 20 participants and concluded that SNS improved evac-
uation difficulty, increased the frequency of defaecation, and de-
creased the time with abdominal pain and bloating. Furthermore,
a systematic review by Sharma 2013 of SNS for constipation in-
cluded 10 studies of which one was a double-blind, placebo-con-
trolled crossover study (Kenefick 2002#). This study found that
SNS can improve bowel frequency and reduce constipation symp-
toms (Sharma 2013).However, our current review which included
two randomised controlled trials involving 61 participants does
not concur with the review by Jarrett 2004 and Sharma 2013.
We found that SNS does not improve symptoms in patients with
constipation but the number of participants was too small to be
conclusive.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
It remains true that SNS is not effective for all patients with severe
faecal incontinence and even some of those who meet the criteria
to progress from temporary to permanent stimulationmay then go
on to experience an increase rather than a reduction in episodes of
faecal incontinence. The practice of employing temporary, percu-
taneous stimulation for a two- to three-week period may identify
those most likely to respond positively to a permanent implant
but does not identify all those for whom a permanent implant will
be beneficial. Further, it must be noted that the failure to implant
patients who have not benefited from a testing phase means that
the true utility of this extra procedure (based on standard statis-
tical measures of diagnostic accuracy) has not been studied. The
adverse event rate leading to removal of the permanent stimulator
was high at 15% in the Leroi 2005# trial but less (6%) in the larger
trial of Tjandra 2008, and less also in the trials by Thin 2015 and
Dinning 2015#.
In summary, this review supports the view that SNS has an im-
portant role for selected patients with FI failing conservative ther-
apies thus reserving direct surgery to the anal sphincter for par-
ticular highly-selected patients or perhaps those failing SNS: such
surgery carries a high risk of serious morbidity and is not always
successful (Baeten 1995; Lehur 1998; Malouf 2000). This posi-
tion may change with further potentially-disruptive technologies
at various stages of trial evaluation (Hotouras 2014; Lehur 2010;
Ratto 2011).
Although there have been considerably fewer published case series
for patients with chronic constipation, available prospective case
series data support a beneficial effect in most, including in the
relatively large European study (Kamm 2010). Despite this the
current clinical view is that the overall results are less good than for
FI (Knowles 2009;Maeda 2010); and that adverse events are more
common (Maeda 2010). The data in the current review involving
two crossover trials of 61 participants do not show any beneficial
effect for SNS when treating patients with constipation but the
information is limited by the small number of participants.
Implications for research
The current literature base in respect of controlled trials must
surely be considered inadequate for an invasive and expensive ther-
apy which, for urinary and faecal incontinence, has now been im-
planted in 145,000 patients worldwide. The proof of effectiveness,
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and indeed efficacy, of SNS is currently based almost entirely on
post-registration (phase IV) data presented by enthusiastic indi-
viduals in ad hoc case series. To date, there has been no definitive
phase III study of effectiveness of SNS versus sham stimulation
nor, importantly, any phase II study designed to combine efficacy
with proof of mechanism. This latter point is important for the
reasons outlined above, i.e. that a proportion of seemingly well-
selected patients fail therapy over time. In the absence of knowl-
edge of mechanism, valid biomarkers for patient selection will be
difficult to determine. Further trials will also need to compare SNS
with other therapies which fall into the minimally-invasive ther-
apy cluster, i.e. between conservative approaches and drugs versus
major reconstructive surgery.
The design of all future trials will need to address the deficiencies
of current trials but this will not be easy. Design points that should
be considered are:
(1) the inadequacy of current outcome measures, especially the
dependency on bowel diaries (Vaizey 2014);
(2) the need formeaningful follow-up (at least one year and ideally
two years or more);
(3) the avoidance of crossover designs with short treatment du-
rations and lack of wash-out periods. (It is accepted that parallel
arm trials require greater recruitment numbers to mitigate against
baseline variances. However, it will be important to assess primary
efficacy in treatment of naïve patients rather than switching the
device on or off in patients who have already been selected on the
basis of successful therapy progression);
(4) attention to participant blinding as well as observer blinding.
(This is complicated by the widespread acknowledgement that
some patients require suprasensory stimulation thus making al-
location concealment and selection of a valid sham therapy diffi-
cult);
(5) interpretation of the temporary testing phase as a diagnostic
test or rather as part of the therapy itself (this has implications for
presenting data as intent-to-treat). As noted above, the validity of
this testing phase has in any case been questioned for discriminant-
value and health-economic reasons.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Dinning 2015#
Methods Randomised crossover trial
Blinding: participant and investigator.
Follow-up: 3 weeks (long-term follow-up not reported)




Median age (range): 42 (19 to 74)
Gender: male (4); female (55).
Duration of symptoms: constipation > 10 years (43), 5 to 10 years (7), and 2 to 5 years
(9)
Received permanent implant: 55
Lost to follow-up: 2
Inclusion criteria:
All of the following: i) A complete bowel movement on less than 3 days per week, for
at least 2 of 3 weeks of the surveillance phase (determined from daily stool diaries).
ii) Aged 18 to 75 yrs; iii) Scintigraphically confirmed slow colonic transit defined as
colonic isotope retention > 20% at 96 h (laboratory upper limit of normal = 1% at
96 h; iv) Normal anorectal manometry, with no evidence of dyssynergia and confirmed
ability to expel rectal balloon; v) With no radiographic evidence of functional (e.g. pelvic
floor dyssynergia) or anatomical (e.g. significant rectocele with retention of contrast,
occluding intussusception) impediment to the expulsion of the radio-opaque contrast;
vi) Failed symptomatic response to standard therapies including osmotic agents, faecal
emollients, laxatives, dietary modification and exercise; and vii) A normal colonoscopy
within 5 years
Exclusion criteria:
Any one of the following; i) Metabolic, neurogenic or endocrine disorder(s) known to
cause constipation; ii) Drugs listing constipation as a potential side effect; or iii) Non-
English speaker or an inability to provide informed consent
Any one of the following; i) Prior abdominal radiotherapy; ii) Prior abdominal surgery
(except cholecystectomy, appendicectomy, inguinal hernia repair, splenectomy, fundo-
plication; oophorectomy or hysterectomy); iii) Current or planned pregnancy; iv) Co-
morbidity considered to put the patient at risk from surgical electrode implantation; or
v) History of malignancy
Interventions All participants underwent peripheral nerve evaluation. Then participants received per-
manent electrode implantation
Intervention: ’suprasensory’ stimulation for 3 weeks
Control: Sham stimulator off for 3 weeks.
Wash out period: 2 weeks.
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Dinning 2015# (Continued)
Outcomes Bowel diary (stool frequency per week; bowel motion per week; feeling of complete
evacuation per week; straining per week; laxative free days per week; soft stool per week;
normal stool per week; hard stool per week; pain score weekly average; bloating score




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Utilised an off-site NHMRC clinical trials
centre automated phone link
Allocation concealment (selection bias) Low risk Utilised an off-site NHMRC clinical trials
centre automated phone link
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Investigator blinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Out of the 59 participants enrolled, 6 with-
drew. The reasons for discontinuation were
depression (n = 1), too far to travel (n = 2),
could not commit (n = 1), pregnancy (n =
1) and severe wound infection (n = 1)
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Low risk None identified
Kahlke 2015#
Methods Randomised crossover trial






Median age (SD): 55.5 (11.8)
Gender: female (16)
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Kahlke 2015# (Continued)
Duration of symptoms: mean (SD): 51.9 (42.7)
Received permanent implant: 16
Lost to follow-up: 0
Inclusion criteria: not mentioned
Exclusion criteria: not mentioned
Interventions All patients had sacral nerve modulation through a staged implantation procedure be-
tween 2009 and 2011. After 26.8 months (median) following implantation 16 out of
the 31 participants agreed to be randomised into a crossover design to stimulation ON
or OFF, each period lasted for 3 weeks. After 6 weeks (i.e. the two periods) participants
while blinded selected the preferred period (ON or OFF) which was continued for a
further 3 months. There was no treatment-free interval




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table utilised.
Allocation concealment (selection bias) Unclear risk Unclear ’Randomised crossover study’.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and key study personnel
blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Personnel assessing outcome were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Out of the 16 participants enrolled, 2 dis-
continued; the reasons cited were partic-
ipant turned stimulator ON with hand-
held device because she had become com-
pletey incontinent (n = 1); participant fell
on lower back leading to breakage of per-
manent lead (n = 1)
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Low risk None identified.
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Kenefick 2002#
Methods Randomised crossover trial
Blinding: participant and investigator
Follow-up: the study consisted of two 2-week intervals with subsensory stimulation
either ’on’ or ’off ’




Age: both aged 36
Gender: female (2)
Duration of symptoms: not stated
Received permanent implant: 2
Inclusion criteria: failed maximal conservative treatment; psychologically stable; normal
sigmoidoscopy; prolonged whole gut transit time; delayed evacuation
Exclusion criteria: not stated
Interventions Both participants had a successful 3-week trial of percutaneous stimulation before one-
stage permanent implantation of a stimulator to the S3 foramen
A Intervention: stimulator On for two weeks with subsensory stimulation
B Control: stimulator Off
No treatment-free period between the weeks
Outcomes Bowel frequency (per 2 weeks); time with pain and bloating (%); Wexner constipation
score (0 to 30); Symptom analogue score (0 to 100); anal manometry
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear: ’Randomised crossover trial’.
Allocation concealment (selection bias) Unclear risk Unclear: ’Randomised crossover trial’.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessor blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Results were reported for everyone who en-
tered the studies and the participants were
analysed in the groups to which they were
originally allocated, effectively resulting in
an intention-to-treat analysis
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Kenefick 2002# (Continued)
Selective reporting (reporting bias) Unclear risk The results of the Short Form 36 quality
of life questionnaire were not reported in
results table
Other bias Low risk None identified.
Leroi 2005#
Methods Randomised crossover trial





Median age (range): 57 (33 to 73)
Gender: male (3); female (31).
Duration of symptoms: < 1 yr (12); 1 to 5 years (12); 5 to 10 years (4); > 10 years (6)
Received permanent implant: 27
Lost to follow-up: 3
Inclusion criteria: faecal incontinence to solid or liquid stool or incapacitating urgency;
failed conservative treatment; demonstrable unilateral bulbo- (or clitorido-) cavernosus
reflex; informed consent given. Participants with external anal sphincter damage on
ultrasound were included in the study if the defect was not considered to be the main
cause of faecal incontinence (i.e. limited defect, ≥ than 30° or limited to one part,
superficial, middle, or deep part of the external anal sphincter).
Exclusion criteria: extensive external anal sphincter defect (defect that was considered to
be the main cause of faecal incontinence)
Interventions Before permanent implantation, participants underwent temporary stimulation, either
percutaneously-placed test stimulation lead (Medtronic InterStim 3057) or permanent
quadripolar lead (model 3093). Both types of leads were connected to an external pulse
generator (model 3625). All participants were tested for 8 to 15 days
For permanent implantation, participants with temporary test stimulation lead under-
went simultaneous implantation of the quadripolar lead and the pulse generator; those
with a lead already in place underwent removal of the percutaneous extension (model
3095) before placement of the pulse generator (model 3023) subcutaneously, below the
superficial fascia, in the upper parts of buttocks ipsilateral to the permanent electrode.
The lead contained four contact electrodes. The electrode combination which allowed
the participant to have the best perception of the perineum muscle and anal sphincter
contraction was chosen for permanent stimulation. Stimulation was continuous with a
pulse width of 210 microseconds, a frequency of 14 pulses per second, and a current
amplitude adapted to the participant’s perception of perineal and anal sphincter muscle
contraction. The stimulator was left on during defaecation and urinary voiding. After a
1- to 3-month optimisation ’on’ phase, participants were randomised to:
A Intervention: stimulation ’on’ for 1 month or
B Control: stimulation ’off ’ for 1 month, then crossed over to the alternative
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Leroi 2005# (Continued)
No treatment-free interval
At the end of the second month, the preferred period (’on’ or ’off ’) was continued for a
further 3 months: if neither was preferred, the stimulator was turned on
Outcomes Episodes of faecal incontinence; faecal urgency; delay in postponing defaecation; bowel
movements; severity of incontinence; quality of life; anal manometry
Notes Severity of incontinence was graded by the Cleveland Clinic Incontinence Scoring Sys-
tem. The score ranged from 0 (normal continence) to 20 (maximum incontinence).
Quality of life was assessed with the French version of the American Society of Colon
and Rectal Surgeons’ Fecal Incontinence Quality of Life Questionnaire (FIQL). In the
questionnaire, four separate QOL domains were explored: lifestyle; coping/behaviour;
depression/self-perception; and embarrassment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number tables.
Allocation concealment (selection bias) Unclear risk Unclear ’Randomised crossover trial’.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants were blinded to treatment al-
located.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Personnel assessing outcome were blinded.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Out of the 34 participants enrolled, 10 pre-
maturely discontinued.The reasons for dis-
continuation were device-related adverse
events (n = 4), protocol violation (n = 3)
, insufficient therapeutic response (n = 1),
no return to follow-up (n = 1), and adverse
event (stroke) not related to SNS (n = 1)
Selective reporting (reporting bias) Low risk All outcomes reported.
Other bias Low risk None identified
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Sørensen 2010#
Methods Randomised crossover trial
Blinding: participant and investigator
Follow-up: 2 weeks
Setting: single centre, Denmark
Intention-to-treat analysis: no
Participants Enrolled: 7
Age: 67 years (60 to 87)
Gender: male (1); female (6).
Duration of symptoms: not stated
Inclusion criteria: not stated
Exclusion criteria: not stated
Interventions Sacral nerve stimulation
A Intervention: stimulator ’on’ for one week
B Control: stimulator ’off ’ for one week
No treatment-free period between the weeks
Outcomes Defaecations/week; faecal incontinence episodes/week; urge episodes/week; passive leak-
age/week; soiling/week; anal manometry
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’shuffling envelopes’
Allocation concealment (selection bias) Unclear risk ’shuffling envelopes’
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and personnel blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Examiners blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No withdrawals
Selective reporting (reporting bias) Unclear risk No information
Other bias Low risk None identified
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Setting: two centres, London, UK
Intention-to-treat analysis: yes
Participants Enrolled: 40
Age: 59 years (mean age)
Gender: male (1); female (39).
Duration of symptoms: not stated
Inclusion criteria:
Age > 18 years
Meets NICE criteria (2007) for symptom severity and failure of previous conservative
therapy
Exclusion criteria:
Inability to provide informed consent for the research study
Severe concomitant medical condition precluding randomization to operative treatment
Neurological diseases, such as diabetic neuropathy, multiple
sclerosis and progressing Parkinson’s disease
Other medical conditions precluding stimulation, such as bleeding
disorders, certain cardiac pacemakers, peripheral vascular
disease
Congenital anorectal anomalies or absence of native rectum as a
result of surgery
Present evidence of external full-thickness rectal prolapse.
Previous rectal surgery (rectopexy/resection) < 12 months ago
Stoma in situ
Chronic bowel disease, such as inflammatory bowel disease,
chronic uncontrolled diarrhoea
Anatomical limitations that would prevent successful placement of
electrodes
Pregnancy or intention to become pregnant.
Previous experience of SNS or PTNS
Interventions SNS vs percutaenous tibial nerve stimulation (PTNS)
Outcomes FI episodes/week (total, urge and passive); symptom severity scoring with Cleveland




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization sequence generated re-
motely by a statistician uninvolved in re-
cruitment, and requests were made and ac-
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Thin 2015 (Continued)
tioned by e-mail
Allocation concealment (selection bias) Low risk Randomization sequence generated re-
motely by a statistician uninvolved in re-
cruitment, and requests were made and ac-
tioned by e-mail
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Investigator blinded but unclear whether
patients were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Investigator blinded but unclear whether
patients were blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Out of 23 participants randomised to the
SNS group, 4 withdrew prior to interven-
tion (intercurrent disease n = 1; symptoms
resolved n = 1; declined further participa-
tion n = 2). Then a further 3 participants
failed temporary SNS. Another participant
who passed the temporary SNS withdrew
from treatment owing to urgent investiga-
tion for new pararectal cyst. Moreover, in
the PTNS group 1 participant withdrew
before intervention (symptoms resolved)
Selective reporting (reporting bias) Low risk Pre-specified outcomes in study protocol
reported.
Other bias Low risk None identified
Tjandra 2008




Setting: single centre, Australia
Intention-to-treat analysis: no
Participants Enrolled: 120
Age: 63.9 (±13.2) in SNS group. 63 (±12.1) in the control group.
Gender: male (9); female (111).
Duration of symptoms: not mentioned
Received permanent implant: 53
Lost to follow-up: none
Inclusion criteria: involuntary passage of solid or liquid stool at least once per week;
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Tjandra 2008 (Continued)
refractory to medical therapy and pelvic floor exercises; and aged 35 to 86 years.
Exclusion criteria: rectal prolapse, inflammatory bowel disease, congenital anorectal mal-
formation, neurologic disorders such as Parkinson’s disease, multiple sclerosis, spinal
cord injury, stoma in situ, pregnancy, external anal sphincter defect of more than 120°
of the circumference, bleeding diathesis, and mental or physical disability precluding
adherence to study protocol
Interventions A (53): SNS (Peripheral nerve evaluation for at least 7 days; then permanent implantation
in participants with ≥ 50% reduction in faecal incontinence episodes per week or ≥
50% reduction in number of days with faecal incontinence per week based on the two-
week bowel diary)
B (60): control group (optimal medical therapy). Optimal medical therapy includes
bulking agents, pelvic floor exercises with a team of dedicated physiotherapists, and
dietary management on fluid and fibre with a team of dieticians
Outcomes Anorectal physiology, severity of incontinence, two-week bowel diary (number of incon-
tinent episodes per week, days with incontinence per week, days with staining per week
and days with pads per week), faecal incontinence quality of life
Continuous data: all mean (SD) N
Episodes of faecal incontinence per week at 3 months: A 2.9 (6.3) 53, B 8.1 (14.1) 60
Episodes of faecal incontinence per week at 12 months: A 3.1 (10.1) 53, B 9.4 (11.8) 60
Days with pads per week at 3 months: A 1.6 (2.6) 53, B 3 (3.8) 60
Days with pads per week at 12 months: A 2.2 (3) 53, B 3.2 (3.1) 60
Days with incontinence per week at 3 months: A 1 (1.7) 53, B 2.9 (2.4) 60
Days with incontinence per week at 12 months: A 1 (1.7) 53, B 3.1 (3.1) 60
Days with staining per week at 3 months: A 1.3 (1.7) 53, B 4.5 (2.1) 60
Days with staining per week at 12 months: A 1.4 (2) 53, B 4.5 (2.3) 60
Cleveland Clinic Incontinence Score [higher = worse] at 3 months: A 1.1 (1) 53, B 12.
1 (2.1) 60
Cleveland Clinic Incontinence Score at 12 months: A 1.2 (1.8)53, B 14.1 (1.9) 60
Quality of Life SF12 [higher = better]:
SF12 Physical at 3 months: A 43.18 (11.68) 53, B 41.5 (9.89) 60
SF12 Physical at 12 months: A 42.22 (9.25) 53, B 40.5 (10.2) 60
SF12 Mental at 3 months: A 50.16 (10.41) 53, B 47.82 (10.66) 60
SF12 Mental at 12 months: A 49.22 (10.88) 53, B 48.22 (10.12) 60
Quality of Life ASCRS Faecal Incontinence Quality of Life Index (FIQL) [higher =
better]:
Lifestyle at 3 months: A 3.34 (0.72) 53, B 2.12 (0.91) 60
Lifestyle at 12 months: A3.31 (0.72) 53, B 2.31 (0.89) 60
Coping at 3 months: A 2.87 (0.8) 53, B 1.85 (0.92) 60
Coping at 12 months : A 2.68 (0.87) 53, B 1.86 (0.88) 60
Depression/self perception at 3 months: A 3.31 (0.77) 53, B 2.68 (0.65) 60
Depression/self perception at 12 months: A 3.25 (0.8) 53, B 2.64 (0.84) 60
Embarrassment at 3 months: A 2.89 (0.85) 53, B 1.7 (0.67) 60
Embarrassment at 12 months: A 2.76 (0.94) 53, B 1.78 (0.61) 60
Anal manometry measures only reported in SNS Group A at 3 months
Ability to defer defecation and worsening of faecal incontinence only reported in SNS
Group A at 3 months
Adverse effects only reported for SNS group: implantation site pain (6 %) particularly
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Tjandra 2008 (Continued)
in slimmer participants,
seroma (2%) which required percutaneous aspiration and
excessive tingling in the vaginal region (9%).
Notes Severity of incontinence was assessed by the Wexner’s incontinence score. The score
ranged from 0 (normal continence) to 20 (maximum incontinence).
Quality of life was assessed using Fecal Incontinence Quality of Life index (FIQL) of
The American Society of Colon and Rectal Surgeons; and the standard short form-12
health survey quality of life questionnaire (SF-12)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation was performed from the
central registry by using sealed envelopes
Allocation concealment (selection bias) Low risk Randomisation was performed from the
central registry by using sealed envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants could not be not blinded and
the control group did not have sham stim-
ulation
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinded assessment for both control and
experimental group
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 7 participants in the SNS group stopped
early but have been counted in the denom-
inators
Selective reporting (reporting bias) Low risk Data from all participants reported
Other bias Low risk None identified
Vaizey 2000#
Methods Randomised crossover trial.
Blinding: participant and investigator.
Follow-up: the study consisted of two 2-week intervals with subsensory stimulation
either ’on’ or ’off ’




Age: 65 and 61 years
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Vaizey 2000# (Continued)
Gender: female (2).
Duration of symptoms: 2.5 years and 3 years.
Inclusion criteria: passive faecal incontinence; intact external sphincter; informed consent
given
Exclusion criteria: not stated
Interventions To implant the unilateral electrode (Medtronic InterStim model 3080), the sacral nerve
root (usually S3) that produces themaximal anal response was identified via percutaneous
needle stimulation. An incision over the sacrum allows access to the sacral foramen.
The permanent electrode was inserted directly and secured to the sacral periosteum
after checking its correct placement by stimulation. A connecting lead (model 7495)
was then tunnelled to the anterior abdominal wall to be connected to the stimulator.
The Implantable Pulse Generator (model 3023) is programmable using telemetry. The
voltage required for stimulation was between 0.5 and 2 volts at a frequency of 15 pulses
per second and a pulse width of 210 µs
A Intervention: stimulator ’on’ for two weeks with subsensory stimulation
B Control: stimulator ’off ’ for two weeks
No treatment-free period between the weeks
Outcomes Episodes of faecal incontinence for liquid or solid stool; anal manometry; psychological
assessment; quality of life
Notes Quality of life was assessed with the SF-36 instrument, score 0 (poor) to 100 (excellent)
, reporting the domains of role-emotional, general health, mental health, bodily pain,
physical functioning, role-physical, social function, and vitality
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Unclear.
Allocation concealment (selection bias) Unclear risk Unclear.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and outcome assessors were
blinded to the allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Participants and outcome assessors were
blinded to the allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk Results were reported for everyone who en-
tered the studies and the participants were
analysed in the groups to which they were
originally allocated, effectively resulting in
an intention-to-treat analysis
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Vaizey 2000# (Continued)
Selective reporting (reporting bias) Unclear risk Psychological assessment not reported in
the results.
Other bias Low risk None identified.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Dinning 2007 No comparator used and study is a trial of wave measurements during the temporary stimulation phase
Dinning 2013 Only reported proportion of participants who satisfied primary outcome measure. Secondary outcomes (pain,
bloating, laxative-free days) and longer term responses of primary outcomes are not available. Author was contacted
Knowles 2012 No report on results of permanent SNS stimulation.
Characteristics of ongoing studies [ordered by study ID]
Borjesson 2013
Trial name or title Sacral nerve stimulation or anal bulking therapy for faecal incontinence - a comparative study







Interventions SNS vs. anal bulking therapy
Outcomes Primary outcomes: proportion of participants responding with > 50% reduction in the number of faecal
incontinence episodes compared to baseline, one year after randomisation
Secondary outcomes: change in number of faecal incontinence episodes, change in deferring time, change in
incontinence score, change in quality of life, and adverse events
Starting date 01/03/2013
Contact information Dr Lars Börjesson
lars.g.borjesson@vgregion.se
Sahlgrenska University Hospital
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Notes Recruitment end date: 01/03/2015
Jayne 2014
Trial name or title SaFaRI: Sacral nerve stimulation versus the FENIX TM magnetic sphincter augmentation for adult faecal
incontinence: a randomised Investigation
Methods Randomised controlled trial, parallel groups
Blinding: unknown
Follow-up: 2 weeks; 6, 12, and 18 months.
Withdrawals: unknown
Setting: multi-centre (at least 20 centres), UK
Intention-to-treat analysis: yes
Participants 350
Interventions FENIXTM magnetic anal sphincter (MAS) vs. SNS
Outcomes Primary outcomes: proportion of patients with device in-situ at 18 months, and proportion of patients
reporting > 50% improvement in continence scores
Secondary outcomes: complications, quality of life, and cost-effectiveness
Starting date 01/01/2015
Contact information Primary contact: Professor David Jayne.
Julie Croft: safari@leeds.ac.uk
Notes Funded by NIHR HTA; co-ordinated by the Clinical Trials Research Unit, University of Leeds
Vallance 2014
Trial name or title Sacral nerve stimulation versus the FENIXTM magnetic anal sphincter for adult faecal incontinence: A
randomised investigation (SaFaRI)
Methods Randomised controlled trial, parallel groups
Blinding: unknown
Follow-up: 2 weeks; 6, 12, and 18 months.
Withdrawals: unknown
Setting: multi-centre (at least 20 centres), UK
Intention-to-treat analysis: yes
Participants 350
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Vallance 2014 (Continued)
Interventions FENIXTM magnetic anal sphincter (MAS) vs. SNS
Outcomes Primary outcomes: proportion of patients with device in-situ at 18 months, and proportion of patients
reporting > 50% improvement in continence scores
Secondary outcomes: complications, quality of life, and cost-effectiveness
Starting date 01/01/2015
Contact information Primary contact: Professor David Jayne.
Julie Croft: safari@leeds.ac.uk
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D A T A A N D A N A L Y S E S
Comparison 1. Faecal incontinence: parallel group data SNS vs medical therapy




participants Statistical method Effect size
1 Episodes of faecal incontinence
per week
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 At 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Days using pads per week 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 At 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Days with incontinence per week 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 At 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Days with faecal staining per
week
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 At 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Cleveland Clinic Incontinence
Score
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 At 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 SF12 Physical 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 At 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 SF12 Mental 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 At 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 FIQL Lifestyle 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 At 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 FIQL Coping/behaviour 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9.2 At 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 FIQL Depression/self
perception
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10.2 At 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 FIQL Embarrassment 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
11.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11.2 At 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
45Sacral nerve stimulation for faecal incontinence and constipation in adults (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Comparison 2. Faecal Incontinence: parallel group data SNS vs PTNS




participants Statistical method Effect size
1 Episodes of faecal incontinence
per week
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Cleveland Clinic Incontinence
Score
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 FIQL Lifestyle 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 FIQL Coping 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 FIQL Depression 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 FIQL Embarrassment 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 EQ-5D 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 At 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 At 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. Faecal incontinence: crossover trials




participants Statistical method Effect size
1 Participants cured and improved
on treatment
Other data No numeric data
2 Episodes of faecal incontinence
per week
Other data No numeric data
3 Ability to defer defaecation
(minutes)
Other data No numeric data
4 Episodes of urgency per week Other data No numeric data
5 Days with pads per week Other data No numeric data
6 Cleveland Clinic Incontinence
Score
Other data No numeric data
7 Quality of life - SF36 Other data No numeric data
8 Quality of life - SF12 Other data No numeric data
9 Quality of life - modified ASCRS Other data No numeric data
10 Quality of life - ASCRS FIQL Other data No numeric data
11 Anorectal manometry Other data No numeric data
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11.1 Maximal resting pressure
(cm H20)
Other data No numeric data
11.2 Maximal squeeze
pressure (cm H20)
Other data No numeric data
11.3 Squeeze pressure
duration (seconds)
Other data No numeric data
11.4 Rectal volume sensation
- threshold (ml)
Other data No numeric data
11.5 Rectal volume sensation
- urge (ml)
Other data No numeric data
11.6 Rectal volume sensation
- maximal tolerated (ml)
Other data No numeric data
11.7 Rectal volume sensation -
constant sensation volume (ml)
Other data No numeric data
12 Bowel movements per week Other data No numeric data
13 Soiling/week Other data No numeric data
14 Days with staining per week Other data No numeric data
15 Days with incontinence per
week
Other data No numeric data
16 Passive leakage/week Other data No numeric data
Comparison 4. Constipation




participants Statistical method Effect size
1 Bowel movements per week Other data No numeric data
2 Time with abdominal pain and
bloating (%)
Other data No numeric data
3 Wexner Constipation Score Other data No numeric data
4 Symptom Analogue Score Other data No numeric data
5 Anorectal manometry Other data No numeric data
5.1 Maximal resting pressure
(cm H 0)
Other data No numeric data
5.2 Maximal squeeze pressure
(cm H 0)
Other data No numeric data
5.3 Rectal volume sensation -
threshold (ml air)
Other data No numeric data
5.4 Rectal volume sensation -
urge (ml air)
Other data No numeric data
5.5 Rectal volume sensation -
maximal tolerated (ml air)
Other data No numeric data
6 Stool frequency (per week) Other data No numeric data
7 Pain score (weekly average) Other data No numeric data
8 Bloating score (weekly average) Other data No numeric data
9 Quality of life - SF36 Other data No numeric data
10 Adverse events Other data No numeric data
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Analysis 1.1. Comparison 1 Faecal incontinence: parallel group data SNS vs medical therapy, Outcome 1
Episodes of faecal incontinence per week.
Review: Sacral nerve stimulation for faecal incontinence and constipation in adults
Comparison: 1 Faecal incontinence: parallel group data SNS vs medical therapy
Outcome: 1 Episodes of faecal incontinence per week








N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Tjandra 2008 53 2.9 (6.3) 60 8.1 (14.1) -5.20 [ -9.15, -1.25 ]
2 At 12 months
Tjandra 2008 53 3.1 (10.1) 60 9.4 (11.8) -6.30 [ -10.34, -2.26 ]
-10 -5 0 5 10
Favours SNS Favours medical
Analysis 1.2. Comparison 1 Faecal incontinence: parallel group data SNS vs medical therapy, Outcome 2
Days using pads per week.
Review: Sacral nerve stimulation for faecal incontinence and constipation in adults
Comparison: 1 Faecal incontinence: parallel group data SNS vs medical therapy
Outcome: 2 Days using pads per week








N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Tjandra 2008 53 1.6 (2.6) 60 3 (3.8) -1.40 [ -2.59, -0.21 ]
2 At 12 months
Tjandra 2008 53 2.2 (3) 60 3.2 (3.1) -1.00 [ -2.13, 0.13 ]
-2 -1 0 1 2
Favours SNS Favours medical
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Analysis 1.3. Comparison 1 Faecal incontinence: parallel group data SNS vs medical therapy, Outcome 3
Days with incontinence per week.
Review: Sacral nerve stimulation for faecal incontinence and constipation in adults
Comparison: 1 Faecal incontinence: parallel group data SNS vs medical therapy
Outcome: 3 Days with incontinence per week








N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Tjandra 2008 53 1 (1.7) 60 2.9 (2.4) -1.90 [ -2.66, -1.14 ]
2 At 12 months
Tjandra 2008 53 1 (1.7) 60 3.1 (3.1) -2.10 [ -3.01, -1.19 ]
-4 -2 0 2 4
Favours SNS Favours medical
Analysis 1.4. Comparison 1 Faecal incontinence: parallel group data SNS vs medical therapy, Outcome 4
Days with faecal staining per week.
Review: Sacral nerve stimulation for faecal incontinence and constipation in adults
Comparison: 1 Faecal incontinence: parallel group data SNS vs medical therapy
Outcome: 4 Days with faecal staining per week








N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Tjandra 2008 53 1.3 (1.7) 60 4.5 (2.1) -3.20 [ -3.90, -2.50 ]
2 At 12 months
Tjandra 2008 53 1.4 (2) 60 4.5 (2.3) -3.10 [ -3.89, -2.31 ]
-4 -2 0 2 4
Favours SNS Favours medical
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Analysis 1.5. Comparison 1 Faecal incontinence: parallel group data SNS vs medical therapy, Outcome 5
Cleveland Clinic Incontinence Score.
Review: Sacral nerve stimulation for faecal incontinence and constipation in adults
Comparison: 1 Faecal incontinence: parallel group data SNS vs medical therapy
Outcome: 5 Cleveland Clinic Incontinence Score








N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Tjandra 2008 53 1.1 (1) 60 12.1 (2.1) -11.00 [ -11.60, -10.40 ]
2 At 12 months
Tjandra 2008 53 1.2 (1.8) 60 14.1 (1.9) -12.90 [ -13.58, -12.22 ]
-10 -5 0 5 10
Favours SNS Favours medical
Analysis 1.6. Comparison 1 Faecal incontinence: parallel group data SNS vs medical therapy, Outcome 6
SF12 Physical.
Review: Sacral nerve stimulation for faecal incontinence and constipation in adults
Comparison: 1 Faecal incontinence: parallel group data SNS vs medical therapy
Outcome: 6 SF12 Physical








N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Tjandra 2008 53 -43.18 (11.68) 60 -41.5 (9.89) -1.68 [ -5.70, 2.34 ]
2 At 12 months
Tjandra 2008 53 -42.22 (9.25) 60 -40.5 (10.2) -1.72 [ -5.31, 1.87 ]
-10 -5 0 5 10
Favours SNS Favours medical
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Analysis 1.7. Comparison 1 Faecal incontinence: parallel group data SNS vs medical therapy, Outcome 7
SF12 Mental.
Review: Sacral nerve stimulation for faecal incontinence and constipation in adults
Comparison: 1 Faecal incontinence: parallel group data SNS vs medical therapy
Outcome: 7 SF12 Mental








N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Tjandra 2008 53 -50.16 (10.41) 60 -47.82 (10.66) -2.34 [ -6.23, 1.55 ]
2 At 12 months
Tjandra 2008 53 -49.22 (10.88) 60 -48.22 (10.12) -1.00 [ -4.89, 2.89 ]
-10 -5 0 5 10
Favours SNS Favours medical
Analysis 1.8. Comparison 1 Faecal incontinence: parallel group data SNS vs medical therapy, Outcome 8
FIQL Lifestyle.
Review: Sacral nerve stimulation for faecal incontinence and constipation in adults
Comparison: 1 Faecal incontinence: parallel group data SNS vs medical therapy
Outcome: 8 FIQL Lifestyle








N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Tjandra 2008 53 -3.34 (0.72) 60 -2.12 (0.91) -1.22 [ -1.52, -0.92 ]
2 At 12 months
Tjandra 2008 53 -3.31 (0.72) 60 -2.31 (0.89) -1.00 [ -1.30, -0.70 ]
-1 -0.5 0 0.5 1
Favours SNS Favours medical
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Analysis 1.9. Comparison 1 Faecal incontinence: parallel group data SNS vs medical therapy, Outcome 9
FIQL Coping/behaviour.
Review: Sacral nerve stimulation for faecal incontinence and constipation in adults
Comparison: 1 Faecal incontinence: parallel group data SNS vs medical therapy
Outcome: 9 FIQL Coping/behaviour








N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Tjandra 2008 53 -2.87 (0.8) 60 -1.85 (0.92) -1.02 [ -1.34, -0.70 ]
2 At 12 months
Tjandra 2008 53 -2.68 (0.87) 60 -1.86 (0.88) -0.82 [ -1.14, -0.50 ]
-2 -1 0 1 2
Favours SNS Favours medical
Analysis 1.10. Comparison 1 Faecal incontinence: parallel group data SNS vs medical therapy, Outcome 10
FIQL Depression/self perception.
Review: Sacral nerve stimulation for faecal incontinence and constipation in adults
Comparison: 1 Faecal incontinence: parallel group data SNS vs medical therapy
Outcome: 10 FIQL Depression/self perception








N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Tjandra 2008 53 -3.31 (0.77) 60 -2.68 (0.65) -0.63 [ -0.89, -0.37 ]
2 At 12 months
Tjandra 2008 53 -3.25 (0.8) 60 -2.64 (0.84) -0.61 [ -0.91, -0.31 ]
-2 -1 0 1 2
Favours SNS Favours medical
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Analysis 1.11. Comparison 1 Faecal incontinence: parallel group data SNS vs medical therapy, Outcome 11
FIQL Embarrassment.
Review: Sacral nerve stimulation for faecal incontinence and constipation in adults
Comparison: 1 Faecal incontinence: parallel group data SNS vs medical therapy
Outcome: 11 FIQL Embarrassment








N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Tjandra 2008 53 -2.89 (0.85) 60 -1.7 (0.67) -1.19 [ -1.47, -0.91 ]
2 At 12 months
Tjandra 2008 53 -2.76 (0.94) 60 -1.78 (0.61) -0.98 [ -1.28, -0.68 ]
-2 -1 0 1 2
Favours SNS Favours medical
Analysis 2.1. Comparison 2 Faecal Incontinence: parallel group data SNS vs PTNS, Outcome 1 Episodes of
faecal incontinence per week.
Review: Sacral nerve stimulation for faecal incontinence and constipation in adults
Comparison: 2 Faecal Incontinence: parallel group data SNS vs PTNS
Outcome: 1 Episodes of faecal incontinence per week





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Thin 2015 15 2.8 (2.5) 16 5.8 (6.9) -3.00 [ -6.61, 0.61 ]
2 At 6 months
Thin 2015 15 3.1 (4) 16 6.3 (6.9) -3.20 [ -7.14, 0.74 ]
-100 -50 0 50 100
Favours SNS Favours PTNS
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Analysis 2.2. Comparison 2 Faecal Incontinence: parallel group data SNS vs PTNS, Outcome 2 Cleveland
Clinic Incontinence Score.
Review: Sacral nerve stimulation for faecal incontinence and constipation in adults
Comparison: 2 Faecal Incontinence: parallel group data SNS vs PTNS
Outcome: 2 Cleveland Clinic Incontinence Score





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Thin 2015 15 10 (5.3) 16 11.7 (4.4) -1.70 [ -5.14, 1.74 ]
2 At 6 months
Thin 2015 15 9.1 (5.4) 16 12.1 (5.2) -3.00 [ -6.74, 0.74 ]
-100 -50 0 50 100
Favours SNS Favours PTNS
Analysis 2.3. Comparison 2 Faecal Incontinence: parallel group data SNS vs PTNS, Outcome 3 FIQL
Lifestyle.
Review: Sacral nerve stimulation for faecal incontinence and constipation in adults
Comparison: 2 Faecal Incontinence: parallel group data SNS vs PTNS
Outcome: 3 FIQL Lifestyle





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Thin 2015 15 -3.1 (0.8) 17 -2.9 (1) -0.20 [ -0.82, 0.42 ]
2 At 6 months
Thin 2015 15 -3 (0.9) 17 -2.8 (0.9) -0.20 [ -0.82, 0.42 ]
-4 -2 0 2 4
Favours SNS Favours PTNS
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Analysis 2.4. Comparison 2 Faecal Incontinence: parallel group data SNS vs PTNS, Outcome 4 FIQL
Coping.
Review: Sacral nerve stimulation for faecal incontinence and constipation in adults
Comparison: 2 Faecal Incontinence: parallel group data SNS vs PTNS
Outcome: 4 FIQL Coping





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Thin 2015 15 -2.5 (0.7) 17 -2.3 (0.8) -0.20 [ -0.72, 0.32 ]
2 At 6 months
Thin 2015 15 -2.5 (0.8) 17 -2 (0.9) -0.50 [ -1.09, 0.09 ]
-4 -2 0 2 4
Favours SNS Favours PTNS
Analysis 2.5. Comparison 2 Faecal Incontinence: parallel group data SNS vs PTNS, Outcome 5 FIQL
Depression.
Review: Sacral nerve stimulation for faecal incontinence and constipation in adults
Comparison: 2 Faecal Incontinence: parallel group data SNS vs PTNS
Outcome: 5 FIQL Depression





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Thin 2015 15 -2.7 (0.8) 17 -2.8 (0.8) 0.10 [ -0.46, 0.66 ]
2 At 6 months
Thin 2015 15 -2.7 (0.7) 17 -2.6 (0.9) -0.10 [ -0.66, 0.46 ]
-4 -2 0 2 4
Favours SNS Favours PTNS
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Analysis 2.6. Comparison 2 Faecal Incontinence: parallel group data SNS vs PTNS, Outcome 6 FIQL
Embarrassment.
Review: Sacral nerve stimulation for faecal incontinence and constipation in adults
Comparison: 2 Faecal Incontinence: parallel group data SNS vs PTNS
Outcome: 6 FIQL Embarrassment





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Thin 2015 15 -2.5 (0.7) 17 -2.2 (0.8) -0.30 [ -0.82, 0.22 ]
2 At 6 months
Thin 2015 15 -2.6 (0.8) 17 -2 (0.8) -0.60 [ -1.16, -0.04 ]
-2 -1 0 1 2
Favours SNS Favours PTNS
Analysis 2.7. Comparison 2 Faecal Incontinence: parallel group data SNS vs PTNS, Outcome 7 EQ-5D.
Review: Sacral nerve stimulation for faecal incontinence and constipation in adults
Comparison: 2 Faecal Incontinence: parallel group data SNS vs PTNS
Outcome: 7 EQ-5D





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 At 3 months
Thin 2015 15 0.66 (0.28) 17 0.6 (0.38) 0.06 [ -0.17, 0.29 ]
2 At 6 months
Thin 2015 15 0.76 (0.22) 17 0.63 (0.37) 0.13 [ -0.08, 0.34 ]
-0.5 -0.25 0 0.25 0.5
Favours SNS Favours PTNS
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Analysis 3.1. Comparison 3 Faecal incontinence: crossover trials, Outcome 1 Participants cured and
improved on treatment.
Participants cured and improved on treatment
Study Cured % Improved %
Leroi 2005# 5/19 26 17/19 89
Thin 2015 3/15 20 10/15 67
Tjandra 2008 22/53 41.5 53/53 100
Vaizey 2000# 1/2 50 2/2 100
Analysis 3.2. Comparison 3 Faecal incontinence: crossover trials, Outcome 2 Episodes of faecal
incontinence per week.
Episodes of faecal incontinence per week



























































































2 (118%) 3.5 (0 to
10)
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5.8 ± 6.9 -4.3 (-
41%)
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53 9.5±12.8 2.9±6.3 -6.4 (-
67%)


































Analysis 3.3. Comparison 3 Faecal incontinence: crossover trials, Outcome 3 Ability to defer defaecation
(minutes).
Ability to defer defaecation (minutes)
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1 (1) 1 (1 to 3) 1 (1 to 3) 1 (1 to 2) 0 1.2 (1 to
1.8)
Analysis 3.4. Comparison 3 Faecal incontinence: crossover trials, Outcome 4 Episodes of urgency per week.
Episodes of urgency per week
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Analysis 3.5. Comparison 3 Faecal incontinence: crossover trials, Outcome 5 Days with pads per week.
Days with pads per week
Study Group Measure Patients Baseline Three
months












and at 12 months
Tjandra
2008
SNS group Mean±SD 53 3.8±3 1.6±2.6 2.2±3 -1.6 (-42%) P < 0.0001 at all
time points com-
pared with base-
line. % change is
reported as the dif-
ference between
baseline and at 12
months
Analysis 3.6. Comparison 3 Faecal incontinence: crossover trials, Outcome 6 Cleveland Clinic Incontinence
Score.
Cleveland Clinic Incontinence Score















14 16 (4.6) 14.6 (4.6) 8.7 (3.6) -5.9 (-
40%)
6.4 (3.3) p<0.05
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0 13 (11 to
18)
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15 16.3±3.3 10.0±5.3 -7.2(-
44%)



















60 15.2±1.6 12.1±2.1 14.1+1.9 -1.1 (-
7%)
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53 16±1.3 1.1±1 1.2+1.8 -14.8 (-
93%)























Analysis 3.7. Comparison 3 Faecal incontinence: crossover trials, Outcome 7 Quality of life - SF36.
Quality of life - SF36
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Analysis 3.8. Comparison 3 Faecal incontinence: crossover trials, Outcome 8 Quality of life - SF12.
Quality of life - SF12





Mean±SD 60 39.29±12.12 41.5±9.89 40.5±10.2 P > 0.05








Mean±SD 60 45.38±12.32 47.82±10.66 48.22±10.12 P > 0.05














Mean±SD 53 45.25±11.09 50.16±10.41 49.22±10.88 P > 0.025 at
12 months. How-
ever, p = 0.005 at
3 months.
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Analysis 3.9. Comparison 3 Faecal incontinence: crossover trials, Outcome 9 Quality of life - modified
ASCRS.
Quality of life - modified ASCRS







Leroi 2005# Baseline Median
(range)
34? 1.7 (1 to 3.8) 1.5 (1 to 2.8) 2.2 (1 to 4.1) 1.3 (1 to 3) The ASCRS
ranges from a
best score of
5 to a worst
score of 1
Leroi 2005# Follow-up Median
(range)
24? 3.2 (1.9 to 4)
P=0.001 ver-
sus baseline
2.7 (1 to 4)
P=0.002 ver-
sus baseline




2.3 (1 to 4)
P=0.002 ver-
sus baseline
Analysis 3.10. Comparison 3 Faecal incontinence: crossover trials, Outcome 10 Quality of life - ASCRS
FIQL.
Quality of life - ASCRS FIQL










Control Baseline Mean±SD 60 2.26±0.98 1.79±0.82 2.59±0.72 1.81±0.52
Tjandra
2008
















SNS Baseline Mean±SD 53 2.39±0.99 1.89±0.82 2.65±0.84 1.93±0.78
Tjandra
2008
3 months Mean±SD 53 3.34±0.72 2.87±0.8 3.31±0.77 2.89±0.85 P <
0.0001 at 3
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Analysis 3.11. Comparison 3 Faecal incontinence: crossover trials, Outcome 11 Anorectal manometry.
Anorectal manometry
Study Group Measure Patients Baseline ’Off ’
period
’On’ period Follow-up Notes
Maximal resting pressure (cm H20)
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SNS Mean±SD 53 40.4±15.9 40.9±21.9 P > 0.



















Maximal squeeze pressure (cm H20)
































































Mean±SD 60 88.5±42.6 Only
performed
at baseline.
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SNS group Mean±SD 53 83.2±39.6 90.2±54.9 P > 0.



















Squeeze pressure duration (seconds)















15 (0 to 45) 21 (4 to 32) 18 (6 to 92) 22 (0 to
110)















20 (5 to 28) 40 (5 to 40) 32 (23 to
38)
25 (4 to 40)
Rectal volume sensation - threshold (ml)
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Rectal volume sensation - maximal tolerated (ml)
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Rectal volume sensation - constant sensation volume (ml)






































Analysis 3.12. Comparison 3 Faecal incontinence: crossover trials, Outcome 12 Bowel movements per week.
Bowel movements per week















14 18.2 (8.7) 10.9 (4.1) -7.3 (- 40
%)
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Analysis 3.13. Comparison 3 Faecal incontinence: crossover trials, Outcome 13 Soiling/week.
Soiling/week
Study Measure Patients ’Off ’ period ’On’ period Change (%) Notes
Sørensen 2010# (95% CI for
mean)
7 1.86 (0.29-3.43) 0.71 (-0.69-2.11) -1.15 (-62%)
Analysis 3.14. Comparison 3 Faecal incontinence: crossover trials, Outcome 14 Days with staining per week.
Days with staining per week
Study Group Measure Patients Baseline Three
months












and at 12 months
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Days with staining per week (Continued)
Tjandra
2008
SNS group Mean±SD 53 4±2.3 1.3±1.7 1.4±2 -2.6 (-65%) P < 0.0001 at all
time points com-
pared with base-
line. % change is
reported as the dif-
ference between
baseline and at 12
months
Analysis 3.15. Comparison 3 Faecal incontinence: crossover trials, Outcome 15 Days with incontinence per
week.
Days with incontinence per week
Study Group Measure Patients Baseline Three
months












and at 12 months
Tjandra
2008
SNS group Mean±SD 53 3.3±2.4 1±1.7 1±1.7 -2.3 (-70%) P < 0.0001 at all
time points com-
pared with base-
line. % change is
reported as the dif-
ference between
baseline and at 12
months
Analysis 3.16. Comparison 3 Faecal incontinence: crossover trials, Outcome 16 Passive leakage/week.
Passive leakage/week
Study Measure Patients ’Off ’ period ’On’ period Change (%) Notes
Sørensen 2010# (95% CI for
mean)
7 0.43 (-0.41 to 1.
27)
0 -0.43 (-100%)
73Sacral nerve stimulation for faecal incontinence and constipation in adults (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.1. Comparison 4 Constipation, Outcome 1 Bowel movements per week.
Bowel movements per week
Study Measure Patients Baseline One year ’Off ’ period ’On’ period Change (%) Notes
Dinning
2015#









2 2 (1 and 3) 8 (8 and 9) 2 (1 and 2) 5 (4 and 5) 3 (150%)
Analysis 4.2. Comparison 4 Constipation, Outcome 2 Time with abdominal pain and bloating (%).
Time with abdominal pain and bloating (%)





2 98 (95 and
100)
0 79 (65 and
93)
33 (0 and 65) -46
Analysis 4.3. Comparison 4 Constipation, Outcome 3 Wexner Constipation Score.
Wexner Constipation Score










Analysis 4.4. Comparison 4 Constipation, Outcome 4 Symptom Analogue Score.
Symptom Analogue Score
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Analysis 4.5. Comparison 4 Constipation, Outcome 5 Anorectal manometry.
Anorectal manometry
Study Measure Patients Baseline One year ’Off ’ period ’On’ period Notes
Maximal resting pressure (cm H 0)
Kenefick
2002#
Mean (range) 2 75 (65 and 84) 85 (82 and 87) 51 (39 and 63) 76 (68 and 84) Stationary pull-
through tech-
nique
Maximal squeeze pressure (cm H 0)
Kenefick
2002#
Mean (range) 2 39 (32 and 46) 78 (52 and
104)
54 (51 and 57) 93 (41 and
145)
Rectal volume sensation - threshold (ml air)
Kenefick
2002#
Mean (range) 2 46 (45 and 47) 40 (20 and 60) 35 (30 and 40) 18 (15 and 20)
Rectal volume sensation - urge (ml air)
Kenefick
2002#
Mean (range) 2 130 (75 and
185)
55 (35 and 75) 70 (60 and 80) 34 (33 and 35)
Rectal volume sensation - maximal tolerated (ml air)
Kenefick
2002#






68 (65 and 70)
Analysis 4.6. Comparison 4 Constipation, Outcome 6 Stool frequency (per week).
Stool frequency (per week)
Study Measure Patients Baseline Off period On period Change (%) Notes
Dinning
2015#
Mean (SD) 53 5.6 (3.7) 6.4 (3.7) 6.6 (3.9) 17.9% Off period is sham, and on period
is suprasensory stimulation
Analysis 4.7. Comparison 4 Constipation, Outcome 7 Pain score (weekly average).
Pain score (weekly average)
Study Measure Patients Baseline Off period On period Percentage change
(%)
Notes
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Pain score (weekly average) (Continued)
Dinning
2015#
Mean (SD) 53 1.4 (0.6) 1.0 (0.8) 0.9 (1.3) -35.7% Off period is sham, and
on period is suprasen-
sory stimulation
Analysis 4.8. Comparison 4 Constipation, Outcome 8 Bloating score (weekly average).
Bloating score (weekly average)
Study Measure Patient Baseline Off period On period hange(%) Notes
Dinning
2015#
Mean (SD) 53 1.6 (0.6) 1.2 (0.7) 1.2 (0.7) -25% Off period is sham, and on period is
suprasensory stimulation
Analysis 4.9. Comparison 4 Constipation, Outcome 9 Quality of life - SF36.
Quality of life - SF36







































49 (8) 46 (10) 48 (10) 45 (9) 51 (8) 48 (10) 46 (11) 46 (10)
Analysis 4.10. Comparison 4 Constipation, Outcome 10 Adverse events.
Adverse events
Study Type Number of adverse events
Dinning 2015# Implanted pulse generator site (IPG) related pain 32
Dinning 2015# Wound infection 12
Dinning 2015# Leg pain/discomfort 4
Dinning 2015# Abdominal pain/discomfort 3
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Adverse events (Continued)
Dinning 2015# Urological 17
Dinning 2015# Tachycardia 1
Dinning 2015# Headache 2
Dinning 2015# Altered mood 2
A D D I T I O N A L T A B L E S
Table 1. Episode of faecal incontinence per week (from Fraser 2004)
Study id Measure Participants Baseline Follow-up p-value Change (%) Notes
Ganio 2002 Mean (range) 31 7.5 (1 to 11) 0.15 (0 to 2) Not reported −7.35 (−98%)
Jarrett 2004 Median
(range)
46 7.5 (1 to 78) 1.00 (0 to 39) < 0.0001 −6.50 (−87%)
Leroi 2001 Mean (SD) 4 3.0 (2.7) 0.50 (0.6) Not reported −2.50 (−83%)










16 2.0 (1 to 5) 0.67 (0 to 1.
67)
Not reported −1.33 (−67%)
Uludag 2002 Mean 34 8.66 0.67 < 0.01 −7.99 (−92%)




pants was 37 at
baseline and 33
at follow-up
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A P P E N D I C E S
Appendix 1. Search strategy for the Incontinence Group Specialised Register






(All searches were of the keyword field of Reference Manager 2012).
Date of the most recent search of the register for this review: 5 February 2015.
Appendix 2. Search strategy for Embase
Embase on OvidSP (1 January 1947 to 2015 Week 5) was searched on 5 February 2015 using the search strategy given in below. Only
the years 2010 to 2015 (inclusive) were searched as these years were not covered by the Cochrane Collaboration’s centralised search of
Embase for CENTRAL at this time .
1. Randomized Controlled Trial/










12. triple blind procedure/
13. or/1-12
14. exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/
15. exp human/ or exp “human tissue, cells or cell components”/
16. 14 and 15
17. 14 not 16
18. 13 not 17
19. continence/
20. (incontinen$ or continen$).tw.
21. incontinence/






28. 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27
29. sacral nerve stimulation/
30. (sacral adj3 stimul*).tw,ot.
31. (sacral adj3 neuromodul*).tw,ot.
32. sns.tw,ot.
33. snm.tw,ot.
34. 29 or 30 or 31 or 32 or 33
35. (2010* or 2011* or 2012* or 2013* or 2014*).em.
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36. 18 and 28 and 34
37. 35 and 36
WH A T ’ S N E W
Last assessed as up-to-date: 5 February 2015.
Date Event Description
17 August 2015 New search has been performed Five new trials were added in this update (Sørensen
2010#; Tjandra 2008;Dinning 2015#; Kahlke 2015#;
Thin 2015). Risk of bias assessment was redone of all
included trials
17 August 2015 New citation required but conclusions have not changed Five new trials were added in this update (Sørensen
2010#; Tjandra 2008;Dinning 2015#; Kahlke 2015#;
Thin 2015). Risk of bias assessment was redone of all
included trials
H I S T O R Y
Protocol first published: Issue 4, 2003
Review first published: Issue 3, 2007
Date Event Description
9 October 2008 Amended Converted to new review format.
23 May 2007 New citation required and conclusions have changed Substantive amendment
10 January 2006 New search has been performed Minor update
C O N T R I B U T I O N S O F A U T H O R S
Amin Abukar andMohamed A Thaha screened the search results, assessed full text studies for inclusion, and undertook data abstraction
and quality assessment. Amin Abukar, Mohamed A Thaha and Charles Knowles drafted the review. Mohamed A Thaha, Noel Thin,
Anthony Ramsanahie, and Charles Knowles provided advice on analysis and interpretation of data and commented on drafts of the
review. Mohamed A Thaha and Charles Knowles provided clinical advice on aspects of the SNS procedure.
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D E C L A R A T I O N S O F I N T E R E S T
Some members of the review author group (NNT, MAT, CHK) are authors of a recently-published overview on the wider topic of
neuromodulation including SNS (Thin 2013). The Royal London Hospital’s team under Professor Knowles heads many original
clinical and methodological studies on neuromodulation, including SNS and PTNS.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research (NIHR), UK.
This project was supported by the National Institute for Health Research, via Cochrane Infrastructure, Cochrane Programme Grant
or Cochrane Incentive funding to the Incontinence Group. The views and opinions expressed therein are those of the authors and do
not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The current review is an update of the previous publication in 2007 (Mowatt 2007) and has included five extra trials.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Constipation [∗therapy]; Cross-Over Studies; Electric Stimulation Therapy [∗methods]; Electrodes, Implanted; Fecal Incontinence
[∗therapy]; Outcome Assessment (Health Care); Sacrum; Spinal Nerves
MeSH check words
Adult; Female; Humans; Male
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